

Annual Shareholder Report

October 31, 2022



Share Class | Ticker

A | KAUAX

B | KAUBX

C | KAUCX

R | KAUFX

Institutional | KAUIX

Federated Hermes Kaufmann Fund

Successor to the Kaufmann Fund, Inc., with performance history since February 21, 1986

A Portfolio of Federated Hermes Equity Funds

Dear Valued Shareholder,

We are pleased to present the Annual Shareholder Report for your fund covering the period from November 1, 2021 through October 31, 2022. This report includes Management's Discussion of Fund Performance, a complete listing of your fund's holdings, performance information and financial statements along with other important fund information.

As a global leader in active, responsible investment management, Federated Hermes is guided by our conviction that responsible investing is the best way to create wealth over the long term. The company provides capabilities across a wide range of asset classes to investors around the world.

In addition, [FederatedInvestors.com](https://www.federatedinvestors.com) offers quick and easy access to valuable resources that include timely fund updates, economic and market insights from our investment strategists and financial planning tools. You can also access many of those insights by following us on Twitter (@FederatedHermes) and LinkedIn.

Thank you for investing with us. We hope you find this information useful and look forward to keeping you informed.

Sincerely,

A handwritten signature in cursive script, appearing to read "J. Christopher Donahue".

J. Christopher Donahue, President

Not FDIC Insured • May Lose Value • No Bank Guarantee

CONTENTS

Management's Discussion of Fund Performance	1
Portfolio of Investments Summary Table	5
Portfolio of Investments	6
Financial Highlights.....	16
Statement of Assets and Liabilities.....	21
Statement of Operations.....	23
Statement of Changes in Net Assets	25
Notes to Financial Statements	26
Report of Independent Registered Public Accounting Firm	42
Shareholder Expense Example	44
Board of Trustees and Trust Officers	46
Evaluation and Approval of Advisory Contract	53
Liquidity Risk Management Program – Annual Evaluation of Adequacy and Effectiveness.....	64
Voting Proxies on Fund Portfolio Securities	66
Quarterly Portfolio Schedule	66

Management's Discussion of Fund Performance (unaudited)

The total return of Federated Hermes Kaufmann Fund (the "Fund"), based on net asset value for the 12-month reporting period ended October 31, 2022, was -32.43% for the Class A Shares, -32.79% for the Class B Shares, -32.74% for the Class C Shares, -32.34% for the Class R Shares and -31.97% for the Institutional Shares. The total return of the Russell Midcap[®] Growth Index (RMCGI),¹ the Fund's broad-based securities market index, was -28.94% for the same period. The total return of the Morningstar Mid-Cap Growth Funds Average (MMCGFA),² a peer group average for the Fund, was -28.76% for the same period. The Fund's and MMCGFA's total returns for the most recently completed fiscal year reflected actual cash flows, transaction costs and expenses, which were not reflected in the total return of the RMCGI.

During the reporting period, the Fund's investment strategy focused on stock selection, sector exposure, international exposure³ and the effect of cash holdings. These were the most significant factors affecting the Fund's performance relative to the RMCGI.

The following discussion will focus on the performance of the Fund's Institutional Shares.

MARKET OVERVIEW

During the reporting period, returns in most global equity markets reversed much of the gains from the prior reporting period as excessive stimulus turned into persistent inflation throughout the year. Inflation and slower GDP growth caused negative impacts to market returns as investors became aware of impacts to both earnings and economic growth. The slower economic growth along with aggressive monetary tightening policy led to slowing industrial orders and job growth. The global economic momentum slowed to a standstill. While most countries have moved past the pandemic, uncertainty around inflation, economic growth, geopolitical uncertainty and potential responses from global central banks remained top concerns for investors.

STOCK SELECTION

The key factors affecting performance from a macroeconomic standpoint were the aggressive monetary responses to inflation due to fiscal policy in the prior year. The monetary tightening, combined with excess fiscal spending rolling off, helped to contribute to the S&P 500[®] Index⁴ sell off for much of 2022. The profitability of many of the companies in which the Fund invested remained strong throughout the reporting period despite the sell off. Fund management continued to seek what it viewed as attractive growth investment opportunities, such as companies it viewed as dominant competitors, possessing strengthening fundamentals, with the potential to deliver both near-term and long-term growth in sales and earnings.

The majority of the Fund's underperformance versus the RMCGI was due to stock selection particularly in Information Technology, Industrials and Financials. Individual companies that made the most positive contribution to Fund performance during the reporting period were Argenx SE, Rhythm Pharmaceuticals, Inc., New Fortress Energy, Inc. and Corcept Therapeutics, Inc. Holdings that negatively impacted Fund performance were Shopify, Inc., GDS Holdings Ltd., Ultragenyx Pharmaceutical, Inc., Blue Owl Capital, Inc. and Veeva Systems, Inc.

SECTOR EXPOSURE

At the end of the reporting period, approximately 59% of the portfolio was invested in four large sectors: Health Care; Information Technology; Financials; and Consumer Discretionary. These sectors have historically provided good opportunities for bottom-up growth investors; and sector exposure positively impacted relative returns for this reporting period.

INTERNATIONAL EXPOSURE

Stock selection of companies domiciled outside the U.S. was a negative contributor to Fund performance; however, their group weight was a positive contributor. Approximately 14.70% of the Fund's assets were invested in such companies during the reporting period.

EFFECT OF CASH HOLDINGS

The Fund had an average cash position of 8.41% during the reporting period. In a declining market, the cash holdings resulted in positive relative Fund performance versus the RMCGI.


- 1 Please see the footnotes to the line graphs below for definitions of, and further information about, the RMCGI.*
- 2 Please see the footnotes to the line graphs below for definitions of, and further information about, the Morningstar peer group.*
- 3 International investing involves special risks including currency risk, increased volatility, political risks and differences in auditing and other financial standards.*
- 4 The S&P 500[®] Index is an unmanaged capitalization-weighted index of 500 stocks designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries. The index is unmanaged, and it is not possible to invest directly in an index.*

FUND PERFORMANCE AND GROWTH OF A \$10,000 INVESTMENT

The graph below illustrates the hypothetical investment of \$10,000¹ in the Federated Hermes Kaufmann Fund (the “Fund”) from October 31, 2012 to October 31, 2022, compared to the Russell Midcap[®] Growth Index (RMCGI)² and the Morningstar Mid-Cap Growth Funds Average (MMCGFA).³ The Average Annual Total Return table below shows returns for each class averaged over the stated periods.

GROWTH OF A \$10,000 INVESTMENT

Growth of \$10,000 as of October 31, 2022



■ Total returns shown for Class A Shares include the maximum sales charge of 5.50% (\$10,000 investment minus \$550 sales charge = \$9,450).

The Fund offers multiple share classes whose performance may be greater than or less than its other share class(es) due to differences in sales charges and expenses. See the Average Annual Total Return table below for the returns of additional classes not shown in the line graph above.

Average Annual Total Returns for the Period Ended 10/31/2022

(returns reflect all applicable sales charges and contingent deferred sales charges as specified below in footnote #1)

	1 Year	5 Years	10 Years
Class A Shares	-36.14%	4.85%	10.46%
Class B Shares	-36.04%	5.31%	10.64%
Class C Shares	-33.33%	5.54%	10.63%
Class R Shares	-32.34%	6.07%	11.10%
Institutional Shares⁴	-31.97%	6.60%	11.43%
RMCGI	-28.94%	8.66%	11.95%
MMCGFA	-28.76%	8.17%	11.15%

Performance data quoted represents past performance which is no guarantee of future results. Investment return and principal value will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Mutual fund performance changes over time and current performance may be lower or higher than what is stated. For current to the most recent month-end performance and after-tax returns, visit FederatedInvestors.com or call 1-800-341-7400. Returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or the redemption of Fund shares. Mutual funds are not obligations of or guaranteed by any bank and are not federally insured.

- 1 Represents a hypothetical investment of \$10,000 in the Fund after deducting applicable sales charges: For Class A Shares, the maximum sales charge of 5.50% (\$10,000 investment minus \$550 sales charge = \$9,450); for Class B Shares, the maximum contingent deferred sales charge is 5.50% on any redemption less than one year from the purchase date; for Class C Shares, the maximum contingent deferred sales charge is 1.00% on any redemption less than one year from the purchase date. The Fund's performance assumes the reinvestment of all dividends and distributions. The RMCGL and MMCGFA have been adjusted to reflect reinvestment of all dividends on securities in the index and the average.*
- 2 The RMCGL measures the performance of the mid-cap growth segment of the U.S. equity universe. It includes those Russell Midcap[®] Index companies with higher price-to-book ratios and higher forecasted growth values. The RMCGL is constructed to provide a comprehensive and unbiased barometer of the mid-cap growth market and is completely reconstituted annually to ensure larger stocks do not distort the performance and characteristics of the true mid-cap growth market. The RMCGL is not adjusted to reflect sales charges, expenses or other fees that the Securities and Exchange Commission requires to be reflected in the Fund's performance. The index is unmanaged and unlike the Fund, is not affected by cash flows. It is not possible to invest directly in an index.*
- 3 Morningstar figures represent the average of the total returns reported by all the funds designated by Morningstar as falling into the respective category indicated. They do not reflect sales charges. The Morningstar figures in the Growth of a \$10,000 Investment line graph are based on historical return information published by Morningstar and reflect the return of the funds comprising the category in the year of publication. Because the funds designated by Morningstar as falling into the category can change over time, the Morningstar figures in the line graph may not match the Morningstar figures in the Average Annual Total Returns table, which reflect the return of the funds that currently comprise the category.*
- 4 The Fund's Institutional Shares commenced operations on December 29, 2016. The Fund offers four other classes of shares: Class A Shares, Class B Shares, Class C Shares and Class R Shares. For the period prior to the commencement of operations of the Institutional Shares, the performance information shown is for the Fund's Class R Shares. In relation to the Institutional Shares, the performance of Class R Shares has not been adjusted to reflect the expenses of the Institutional Shares since the Institutional Shares have a lower expense ratio than the expense ratio of the Class R Shares. The performance of Class R Shares has been adjusted to remove any voluntary waiver of Fund expenses related to the Class R Shares that may have occurred during the period prior to the commencement of operations of the Institutional Shares.*

Portfolio of Investments Summary Table (unaudited)

At October 31, 2022, the Fund's sector composition¹ was as follows:

Sector Composition	Percentage of Total Net Assets
Health Care	39.7%
Financials	7.9%
Consumer Discretionary	6.4%
Information Technology	5.5%
Energy	5.2%
Real Estate	5.0%
Materials	4.5%
Industrials	4.5%
Consumer Staples	1.7%
Utilities	1.6%
Communication Services	1.0%
U.S. Treasury Notes	2.4%
Securities Lending Collateral ²	16.7%
Cash Equivalents ³	0.9%
Other Assets and Liabilities—Net ⁴	(3.0)%
TOTAL	100%

- ¹ Except for Securities Lending Collateral, Cash Equivalents and Other Assets and Liabilities, sector classifications are based upon, and individual portfolio securities are assigned to, the classifications of the Global Industry Classification System (GICS), except that the Adviser assigns a classification to securities not classified by the GICS and to securities for which the Adviser does not have access to the classification made by the GICS.
- ² Represents cash collateral received for portfolio securities on loan that may be invested in affiliated money market funds, other money market instruments and/or repurchase agreements.
- ³ Cash Equivalents include any investments in money market mutual funds and/or overnight repurchase agreements other than those representing securities lending collateral.
- ⁴ Assets, other than investments in securities, less liabilities. See Statement of Assets and Liabilities.

Portfolio of Investments

October 31, 2022

Shares or Principal Amount		Value
	COMMON STOCKS—82.6%	
	Communication Services—1.0%	
65,000	¹ Take-Two Interactive Software, Inc.	\$ 7,701,200
1,000,000	¹ ZoomInfo Technologies, Inc.	44,530,000
	TOTAL	52,231,200
	Consumer Discretionary—6.3%	
270,000	¹ Airbnb, Inc.	28,865,700
100,000	¹ Alibaba Group Holding Ltd., ADR	6,358,000
400,000	¹ Amazon.com, Inc.	40,976,000
15,850	¹ Chipotle Mexican Grill, Inc.	23,748,531
150,000	Choice Hotels International, Inc.	19,476,000
50,000	¹ Etsy, Inc.	4,695,500
280,000	¹ Floor & Decor Holdings, Inc.	20,543,600
25,000	Home Depot, Inc.	7,403,250
50,000	¹ Las Vegas Sands Corp.	1,900,500
57,500	¹ Lululemon Athletica, Inc.	18,919,800
10,000	¹ Mercadolibre, Inc.	9,016,200
240,000	Moncler S.p.A.	10,363,147
19,984,201	NagaCorp Ltd.	9,102,471
400,000	¹ Planet Fitness, Inc.	26,192,000
1,200,000	^{1,2} Sportradar Group AG	11,880,000
10,000	Vail Resorts, Inc.	2,191,300
446,684	Wingstop, Inc.	70,750,279
192,000	¹ YETI Holdings, Inc.	6,159,360
	TOTAL	318,541,638
	Consumer Staples—1.7%	
30,300	Costco Wholesale Corp.	15,195,450
38,000	Estee Lauder Cos., Inc., Class A	7,618,620
550,000	Philip Morris International, Inc.	50,517,500
905,000	¹ The Duckhorn Portfolio, Inc.	13,231,100
	TOTAL	86,562,670
	Energy—5.2%	
450,500	Cheniere Energy, Inc.	79,472,705
2,343,000	² New Fortress Energy, Inc.	129,029,010
222,500	Pioneer Natural Resources, Inc.	57,051,225
	TOTAL	265,552,940
	Financials—7.9%	
996,000	Apollo Global Management, Inc.	55,138,560

**Shares or
Principal
Amount**

Value

COMMON STOCKS—continued		
Financials—continued		
81,350	BlackRock, Inc.	\$ 52,544,779
9,000,000	¹ Blue Owl Capital, Inc.	90,180,000
1	^{1,3,4} FA Private Equity Fund IV LP	342,495
2,102,000	FinecoBank Banca Fineco SPA	28,387,652
500,000	¹ Hamilton Lane Alliance Holdings I, Inc.	4,985,000
699,000	Hamilton Lane, Inc.	41,814,180
980,000	KKR & Co., Inc., Class Common	47,657,400
75,000	MSCI, Inc., Class A	35,164,500
150,000	S&P Global, Inc.	48,187,500
	TOTAL	404,402,066
Health Care—39.4%		
155,800	Abbott Laboratories	15,414,852
1,942,492	^{1,2} Akouos, Inc.	25,582,620
1,108,422	^{1,2} Albireo Pharma, Inc.	22,744,819
2,225,000	¹ Alector, Inc.	20,470,000
1,135,000	¹ Amphastar Pharmaceuticals, Inc.	35,071,500
774,637	^{1,2} Amylyx Pharmaceuticals, Inc.	27,631,302
1,117,802	^{1,2} AnaptysBio, Inc.	32,248,588
2,000,000	^{1,2} Annexon, Inc.	9,560,000
156,700	¹ Apellis Pharmaceuticals, Inc.	9,478,783
133,281	Apollo Endosurgery, Inc.	858,330
1	^{3,4} Apollo Investment Fund V	83,588
1,971,300	^{1,2} Arcturus Therapeutics Holdings, Inc.	34,892,010
760,000	Argenx SE	295,668,068
2,265,000	¹ aTyr Pharma, Inc.	5,594,550
1,125,000	¹ Avidity Biosciences LLC	16,065,000
300,000	¹ Catalent, Inc.	19,719,000
250,000	^{1,2} Century Therapeutics, Inc.	2,625,000
267,745	^{1,2} Century Therapeutics, Inc.	2,811,322
454,099	¹ Cerevel Therapeutics Holdings	12,696,608
124,489	¹ Chinook Therapeutics, Inc.	2,707,636
5,100,000	¹ Corcept Therapeutics, Inc.	145,860,000
195,000	^{1,2} CRISPR Therapeutics AG	10,206,300
490,000	Danaher Corp.	123,318,300
121,500	¹ Denali Therapeutics, Inc.	3,484,620
1,084,800	¹ Dexcom, Inc.	131,022,144
6,572,140	^{1,2} Dynavax Technologies Corp.	75,251,003
238,100	¹ Edwards Lifesciences Corp.	17,245,583
34,500	Eli Lilly & Co.	12,492,105

**Shares or
Principal
Amount**

Value

COMMON STOCKS—continued

Health Care—continued

121,800	¹ Fate Therapeutics, Inc.	\$ 2,548,056
500,000	¹ Fusion Pharmaceuticals, Inc.	1,237,500
255,181	¹ Galapagos N.V.	11,633,845
1,500,000	^{1,2} Gamida Cell Ltd.	2,685,000
125,700	Genmab A/S	48,477,517
502,834	^{1,2} Genmab A/S, ADR	19,364,137
200,000	^{1,2} Gossamer Bio, Inc.	2,220,000
679,512	¹ Gracell Biotechnologies, Inc., ADR	2,167,643
320,970	¹ Graphite Bio, Inc.	1,126,605
170,000	¹ Guardant Health, Inc.	8,415,000
1,220,800	¹ IDEAYA Biosciences, Inc.	20,619,312
39,300	¹ IDEXX Laboratories, Inc.	14,135,424
94,700	illumina, Inc.	21,669,254
400,000	¹ Immatics N.V.—Restricted	4,520,000
185,000	¹ Insulet Corp.	47,879,850
563,800	¹ Intellia Therapeutics, Inc.	29,757,364
59,000	¹ Intuitive Surgical, Inc.	14,541,730
164,133	^{1,3} Laronde, Inc.	3,559,240
1	^{1,3,4} Latin Healthcare Fund	268,383
1,142,500	¹ Legend Biotech Corp., ADR	56,919,350
500,000	^{1,2} Lyell Immunopharma, Inc.	2,940,000
1,515,000	^{1,2} Merus N.V.	31,057,500
650,000	¹ Minerva Neurosciences, Inc.	1,722,500
51,000	¹ Mirati Therapeutics, Inc.	3,433,320
200,000	^{1,2} Morphic Holding, Inc.	5,602,000
25,000	¹ Natera, Inc.	1,174,000
530,000	¹ Orchard Therapeutics PLC	239,666
7,000,000	^{1,2} Orchard Therapeutics PLC, ADR	3,165,400
220,000	¹ Privia Health Group, Inc.	7,365,600
1,240,000	Regulus Therapeutics, Inc.	1,922,000
1,356,000	¹ Regulus Therapeutics, Inc.	2,101,800
180,000	¹ Repligen Corp.	32,848,200
3,215,300	¹ Rezolute, Inc.	5,433,857
3,847,000	^{1,2} Rhythm Pharmaceuticals, Inc.	96,828,990
358,200	^{1,2} Sarepta Therapeutics, Inc.	40,841,964
1,540,000	^{1,2} Scynexis, Inc.	3,557,400
11,990,000	¹ Seres Therapeutics, Inc.	106,231,400
959,018	^{1,3} Soteira, Inc.	0
59,700	Stryker Corp.	13,685,628

**Shares or
Principal
Amount**

Value

COMMON STOCKS—continued		
Health Care—continued		
418,500	¹ Tandem Diabetes Care, Inc.	\$ 23,498,775
1,500,000	¹ Ultragenyx Pharmaceutical, Inc.	60,690,000
500,000	¹ Veeva Systems, Inc.	83,970,000
870,000	^{1,2} Verve Therapeutics, Inc.	32,799,000
2,853,040	Zai Lab Ltd.	6,373,520
505,000	¹ Zentalis Pharmaceuticals, LLC	12,670,450
	TOTAL	2,004,701,811
Industrials—4.5%		
1,370,000	¹ CoStar Group, Inc.	113,326,400
33,600	Deere & Co.	13,299,552
32,700	¹ Generac Holdings, Inc.	3,790,257
337,400	HEICO Corp.	54,874,736
249,400	¹ Mercury Systems, Inc.	12,070,960
125,000	Trane Technologies PLC	19,953,750
135,000	¹ Trex Co., Inc.	6,492,150
400,000	¹ Upwork, Inc.	5,380,000
	TOTAL	229,187,805
Information Technology—5.5%		
32,800	¹ Adobe, Inc.	10,446,800
350,000	¹ Advanced Micro Devices, Inc.	21,021,000
41,600	Ansys, Inc.	9,200,256
200,000	¹ Coupa Software, Inc.	10,646,000
1,059,322	^{1,3,4} Expand Networks Ltd.	0
1,695,000	^{1,2} GDS Holdings Ltd., ADR	14,627,850
6,300	¹ Keysight Technologies, Inc.	1,097,145
570,000	Marvell Technology, Inc.	22,617,600
275,000	¹ Q2 Holdings, Inc.	8,536,000
300,000	¹ Radware Ltd.	6,906,000
250,000	¹ Rapid7, Inc.	11,317,500
75,000	¹ Salesforce, Inc.	12,194,250
3,751	^{1,3,4} Sensable Technologies, Inc.	0
75,000	¹ ServiceNow, Inc.	31,555,500
615,000	¹ Shopify, Inc.	21,051,450
170,000	¹ Splunk, Inc.	14,128,700
190,800	¹ Tyler Technologies, Inc.	61,691,364
750,000	¹ WM Technology, Inc.	1,537,500
150,000	¹ Workday, Inc.	23,373,000
	TOTAL	281,947,915

Shares or Principal Amount		Value
	COMMON STOCKS—continued	
	Materials—4.5%	
1,150,000	⁴ Agnico Eagle Mines Ltd.	\$ 50,554,000
100,000	Albemarle Corp.	27,987,000
1,825,000	Barrick Gold Corp.	27,429,750
1,100,000	Newmont Corp.	46,552,000
237,600	Sherwin-Williams Co.	53,467,128
226,200	Westlake Corp.	21,862,230
	TOTAL	227,852,108
	Real Estate—5.0%	
700,000	Americold Realty Trust, Inc.	16,975,000
300,000	Crown Castle International Corp.	39,978,000
850,000	Easterly Government Properties, Inc.	14,781,500
300,000	National Storage Affiliates Trust	12,798,000
1,825,000	Physicians Realty Trust	27,484,500
400,000	ProLogis, Inc.	44,300,000
250,000	Ryman Hospitality Properties	22,230,000
600,000	STAG Industrial, Inc.	18,954,000
50,000	Sun Communities, Inc.	6,742,500
1,500,000	VICI Properties, Inc.	48,030,000
	TOTAL	252,273,500
	Utilities—1.6%	
200,000	Duke Energy Corp.	18,636,000
825,000	NextEra Energy, Inc.	63,937,500
	TOTAL	82,573,500
	TOTAL COMMON STOCKS (IDENTIFIED COST \$2,655,486,729)	4,205,827,153
	U.S. TREASURIES—2.4%	
	U.S. Treasury Notes—2.4%	
\$ 60,000,000	United States Treasury Note, 2.750%, 8/15/2032	53,755,392
75,000,000	United States Treasury Note, 2.875%, 5/15/2032	68,039,693
	TOTAL U.S. TREASURIES (IDENTIFIED COST \$129,090,039)	121,795,085
	PREFERRED STOCKS—0.2%	
	Health Care—0.2%	
1,903,967	³ CeQur SA	9,711,857
	Information Technology—0.0%	
679,348	^{1,3,4} Multiplex, Inc., Pfd., Series C	0
	TOTAL PREFERRED STOCKS (IDENTIFIED COST \$15,361,730)	9,711,857

Shares or Principal Amount		Value
	CORPORATE BOND—0.1%	
	Consumer Discretionary—0.1%	
\$ 3,000,000	NagaCorp Ltd., Sr. Unsecd. Note, 7.950%, 7/6/2024 (IDENTIFIED COST \$2,642,750)	\$ 2,610,000
	WARRANTS—0.1%	
	Health Care—0.1%	
801,900	¹ Catabasis Pharmaceuticals, Inc., Warrants 6/22/2023	2,566
421,550	¹ Catabasis Pharmaceuticals, Inc., Warrants 2/8/2024	40,426
200,970	¹ Rezolute, Inc., Warrants 10/8/2027	106,554
56,800	¹ Rezolute, Inc., Warrants 1/1/2099	95,992
1,690,301	¹ Rezolute, Inc., Warrants 12/31/2099	2,856,609
101,700	¹ Scynexis, Inc., Warrants 3/8/2023	0
853,000	¹ Scynexis, Inc., Warrants 5/21/2024	136,395
1,706,000	¹ Scynexis, Inc., Warrants 1/1/2099	3,940,860
167,251	¹ Scynexis, Inc., Warrants 4/26/2029	241,193
	TOTAL WARRANTS (IDENTIFIED COST \$17,450,879)	7,420,595
	INVESTMENT COMPANIES—17.6%	
47,261,098	Federated Hermes Government Obligations Fund, Premier Shares, 2.94% ⁵	47,261,098
849,519,541	Federated Hermes Institutional Prime Value Obligations Fund, Institutional Shares, 3.08% ⁵	849,229,625
	TOTAL INVESTMENT COMPANIES (IDENTIFIED COST \$896,533,962)	896,490,723
	TOTAL INVESTMENT IN SECURITIES—103.0% (IDENTIFIED COST \$3,716,566,089) ⁶	5,243,855,413
	OTHER ASSETS AND LIABILITIES - NET—(3.0)% ⁷	(151,400,161)
	TOTAL NET ASSETS—100%	\$5,092,455,252

An affiliated company is a company in which the Fund, alone or in combination with other funds, has ownership of at least 5% of the voting shares. Transactions with the affiliated companies during the period ended October 31, 2022, were as follows:

Affiliated	Value as of 10/31/2021	Purchases at Cost*	Proceeds from Sales*
Health Care:			
Akouos, Inc.	\$ 10,883,542	\$ 2,701,634	\$ —
Albireo Pharma, Inc.	\$ 38,687,981	\$ —	\$ (4,896,333)
Alector, Inc.	\$ 54,350,000	\$ —	\$ (2,754,051)
Amphastar Pharmaceuticals, Inc.	\$ 23,661,694	\$ —	\$ (4,648,526)
AnaptysBio, Inc.	\$ 19,183,168	\$ 11,975,310	\$ —
Annexon, Inc.	\$ 16,310,000	\$ 8,027,243	\$ —
Arcturus Therapeutics Holdings, Inc.	\$ 61,959,080	\$ 22,066,085	\$ —
aTyr Pharma, Inc.	\$ 19,456,350	\$ —	\$ —
Avidity Biosciences LLC	\$ 25,312,500	\$ —	\$ —
Dynavax Technologies Corp.	\$ 149,922,778	\$ 10,688,332	\$ (21,108,546)
Gamida Cell Ltd.**	\$ 16,941,664	\$ 2,092,206	\$ (8,939,888)
IDEAYA Biosciences, Inc.	\$ 18,884,352	\$ 3,570,000	\$ —
Merus N.V.	\$ 42,075,000	\$ 2,850,000	\$ (1,816,084)
Minerva Neurosciences, Inc.	\$ 7,280,000	\$ —	\$ —
Orchard Therapeutics PLC	\$ 1,017,600	\$ —	\$ —
Orchard Therapeutics PLC, ADR	\$ 13,305,600	\$ 33,047	\$ —
Rezolute, Inc.	\$ 9,760,000	\$ 6,423,140	\$ —
Rezolute, Inc., Warrants 10/8/2027	\$ —	\$ —	\$ —
Rezolute, Inc., Warrants 1/1/2099	\$ 363,520	\$ —	\$ —
Rezolute, Inc., Warrants 12/31/2099	\$ —	\$ 6,421,454	\$ —
Rhythm Pharmaceuticals, Inc.	\$ 4,760,536	\$ 48,886,545	\$ (10,565,023)
Scynexis, Inc.	\$ 2,603,942	\$ 5,833,004	\$ —
Scynexis, Inc., Warrants 3/8/2023	\$ 15,265	\$ —	\$ —
Scynexis, Inc., Warrants 5/21/2024	\$ 1,270,970	\$ —	\$ —
Scynexis, Inc., Warrants 1/1/2099	\$ 8,547,060	\$ —	\$ —
Scynexis, Inc., Warrants 4/26/2029	\$ —	\$ —	\$ —
Seres Therapeutics, Inc.	\$ 36,480,000	\$ 19,467,882	\$ (924,794)
Soteira, Inc.	\$ —	\$ —	\$ —
Ultragenyx Pharmaceutical, Inc.	\$ 140,985,600	\$ —	\$ (12,670,431)
Information Technology:			
WM Technology, Inc.	\$ 22,980,600	\$ —	\$ (6,173,368)
Affiliated issuers no longer in the portfolio at period end	\$ 184,658,871	\$ 30,377,710	\$ (93,148,665)
TOTAL OF AFFILIATED COMPANIES TRANSACTIONS	\$931,657,673	\$181,413,592	\$(167,645,709)

Change in Unrealized Appreciation/Depreciation*	Net Realized Gain/(Loss)*	Value as of 10/31/2022	Shares Held as of 10/31/2022	Dividend Income*
\$ 11,997,444	\$ —	\$ 25,582,620	1,942,492	\$—
\$ (7,360,918)	\$ (3,685,911)	\$ 22,744,819	1,108,422	\$—
\$ (28,048,006)	\$ (3,077,943)	\$ 20,470,000	2,225,000	\$—
\$ 14,045,319	\$ 2,013,013	\$ 35,071,500	1,135,000	\$—
\$ 1,090,110	\$ —	\$ 32,248,588	1,117,802	\$—
\$ (14,777,243)	\$ —	\$ 9,560,000	2,000,000	\$—
\$ (49,133,155)	\$ —	\$ 34,892,010	1,971,300	\$—
\$ (13,861,800)	\$ —	\$ 5,594,550	2,265,000	\$—
\$ (9,247,500)	\$ —	\$ 16,065,000	1,125,000	\$—
\$ (63,139,644)	\$ (1,111,917)	\$ 75,251,003	6,572,140	\$—
\$ 4,045,574	\$ (11,454,556)	\$ 2,685,000	1,500,000	\$—
\$ (1,835,040)	\$ —	\$ 20,619,312	1,220,800	\$—
\$ (11,342,953)	\$ (708,463)	\$ 31,057,500	1,515,000	\$—
\$ (5,557,500)	\$ —	\$ 1,722,500	650,000	\$—
\$ (777,934)	\$ —	\$ 239,666	530,000	\$—
\$ (10,173,247)	\$ —	\$ 3,165,400	7,000,000	\$—
\$ (10,749,283)	\$ —	\$ 5,433,857	3,215,300	\$—
\$ 106,554	\$ —	\$ 106,554	200,970	\$—
\$ (267,528)	\$ —	\$ 95,992	56,800	\$—
\$ (3,564,845)	\$ —	\$ 2,856,609	1,690,301	\$—
\$ 59,161,909	\$ (5,414,977)	\$ 96,828,990	3,847,000	\$—
\$ (4,879,546)	\$ —	\$ 3,557,400	1,540,000	\$—
\$ (15,265)	\$ —	\$ —	101,700	\$—
\$ (1,134,575)	\$ —	\$ 136,395	853,000	\$—
\$ (4,606,200)	\$ —	\$ 3,940,860	1,706,000	\$—
\$ 241,193	\$ —	\$ 241,193	167,251	\$—
\$ 51,691,146	\$ (482,834)	\$106,231,400	11,990,000	\$—
\$ —	\$ —	\$ —	959,018	\$—
\$ (71,074,249)	\$ 3,449,080	\$ 60,690,000	1,500,000	\$—
\$ (10,168,100)	\$ (5,101,632)	\$ 1,537,500	750,000	\$—
\$ (601,683)	\$(121,286,233)	\$ —	—	\$—
\$(179,936,965)	\$(146,862,373)	\$618,626,218	62,455,296	\$—

* A portion of the amount shown was recorded when the Fund no longer had ownership of at least 5% of the voting shares.

** At October 31, 2022, the Fund no longer has ownership of at least 5% of the voting shares.

Affiliated fund holdings are investment companies which are managed by the Adviser or an affiliate of the Adviser. Transactions with affiliated fund holdings during the period ended October 31, 2022, were as follows:

	Federated Hermes Government Obligations Fund, Premier Shares*	Federated Hermes Institutional Prime Value Obligations Fund, Institutional Shares*	Total of Affiliated Transactions
Value as of 10/31/2021	\$ 66,719,105	\$ 608,215,159	\$ 674,934,264
Purchases at Cost	\$ 723,717,299	\$ 2,219,857,293	\$ 2,943,574,592
Proceeds from Sales	\$(743,175,306)	\$(1,978,550,484)	\$(2,721,725,790)
Change in Unrealized Appreciation/ Depreciation	N/A	\$ (82,707)	\$ (82,707)
Net Realized Gain/(Loss)	N/A	\$ (209,636)	\$ (209,636)
Value as of 10/31/2022	\$ 47,261,098	\$ 849,229,625	\$ 896,490,723
Shares Held as of 10/31/2022	47,261,098	849,519,541	896,780,639
Dividend Income	\$ 316,397	\$ 7,737,799	\$ 8,054,196
Gain Distributions Received	\$ —	\$ 40,129	\$ 40,129

* All or a portion of the balance/activity for the fund relates to cash collateral received on securities lending transactions.

1 Non-income-producing security.

2 All or a portion of these securities are temporarily on loan to unaffiliated broker/dealers.

3 Market quotations and price evaluations are not available. Fair value determined using significant unobservable inputs in accordance with procedures established by and under the general supervision of the Fund's Adviser acting through its Valuation Committee.

4 Denotes a restricted security that either: (a) cannot be offered for public sale without first being registered, or availing of an exemption from registration, under the Securities Act of 1933; or (b) is subject to a contractual restriction on public sales. At October 31, 2022, these restricted securities amounted to \$51,248,466, which represented 1.0% of total net assets.

5 7-day net yield.

6 The cost of investments for federal tax purposes amounts to \$3,736,818,119.

7 Assets, other than investments in securities, less liabilities. See Statement of Assets and Liabilities.

Note: The categories of investments are shown as a percentage of total net assets at October 31, 2022.

Various inputs are used in determining the value of the Fund's investments. These inputs are summarized in the three broad levels listed below:

Level 1—quoted prices in active markets for identical securities.

Level 2—other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). Also includes securities valued at amortized cost.

Level 3—significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used, as of October 31, 2022, in valuing the Fund's assets carried at fair value:

Valuation Inputs

	Level 1— Quoted Prices	Level 2— Other Significant Observable Inputs	Level 3— Significant Unobservable Inputs	Total
Equity Securities:				
Common Stocks				
Domestic	\$3,506,003,597	\$ —	\$ 4,253,706	\$3,510,257,303
International	285,563,630	410,006,220	—	695,569,850
Preferred Stocks				
International	—	—	9,711,857	9,711,857
Domestic	—	—	0	0
Debt Securities:				
U.S. Treasuries	—	121,795,085	—	121,795,085
Corporate Bond	—	2,610,000	—	2,610,000
Warrants	2,952,601	4,467,994	—	7,420,595
Investment Companies	896,490,723	—	—	896,490,723
TOTAL SECURITIES	\$4,691,010,551	\$538,879,299	\$13,965,563	\$5,243,855,413

The following acronym(s) are used throughout this portfolio:

ADR—American Depositary Receipt

See Notes which are an integral part of the Financial Statements

Financial Highlights – Class A Shares

(For a Share Outstanding Throughout Each Period)

	Year Ended October 31,				
	2022	2021	2020	2019	2018
Net Asset Value, Beginning of Period	\$7.77	\$6.80	\$6.27	\$6.03	\$6.06
Income From Investment Operations:					
Net investment income (loss) ¹	(0.06)	(0.10)	(0.09)	(0.05)	(0.06)
Net realized and unrealized gain (loss)	(2.29)	1.57	1.32	1.09	0.69
TOTAL FROM INVESTMENT OPERATIONS	(2.35)	1.47	1.23	1.04	0.63
Less Distributions:					
Distributions from net realized gain	(0.65)	(0.50)	(0.70)	(0.80)	(0.66)
Net Asset Value, End of Period	\$4.77	\$7.77	\$6.80	\$6.27	\$6.03
Total Return²	(32.43)%	22.37%	21.52%	19.52%	11.64%

Ratios to Average Net Assets:

Net expenses ³	1.95%	1.92%	1.94%	1.95%	1.95%
Net investment income (loss)	(1.09)%	(1.41)%	(1.38)%	(0.81)%	(1.02)%
Expense waiver/reimbursement ⁴	0.03%	0.04%	0.03%	0.03%	0.03%

Supplemental Data:

Net assets, end of period (000 omitted)	\$1,196,453	\$2,023,577	\$1,808,715	\$1,629,524	\$1,491,496
Portfolio turnover ⁵	25%	34%	38%	42%	33%

- Per share numbers have been calculated using the average shares method.*
- Based on net asset value, which does not reflect the sales charge, redemption fee or contingent deferred sales charge, if applicable.*
- Amount does not reflect net expenses incurred by investment companies in which the Fund may invest.*
- This expense decrease is reflected in both the net expense and the net investment income (loss) ratios shown above. Amount does not reflect expense waiver/reimbursement recorded by investment companies in which the Fund may invest.*
- Securities that mature are considered sales for purposes of this calculation.*

See Notes which are an integral part of the Financial Statements

Financial Highlights – Class B Shares

(For a Share Outstanding Throughout Each Period)

	Year Ended October 31,				
	2022	2021	2020	2019	2018
Net Asset Value, Beginning of Period	\$5.83	\$5.24	\$5.00	\$4.99	\$5.15
Income From Investment Operations:					
Net investment income (loss) ¹	(0.07)	(0.11)	(0.09)	(0.06)	(0.08)
Net realized and unrealized gain (loss)	(1.67)	1.20	1.03	0.87	0.58
TOTAL FROM INVESTMENT OPERATIONS	(1.74)	1.09	0.94	0.81	0.50
Less Distributions:					
Distributions from net realized gain	(0.65)	(0.50)	(0.70)	(0.80)	(0.66)
Net Asset Value, End of Period	\$3.44	\$5.83	\$5.24	\$5.00	\$4.99
Total Return²	(32.79)%	21.73%	21.10%	18.88%	11.11%
Ratios to Average Net Assets:					
Net expenses ³	2.44%	2.42%	2.44%	2.45%	2.46%
Net investment income (loss)	(1.61)%	(1.92)%	(1.87)%	(1.32)%	(1.54)%
Expense waiver/reimbursement ⁴	0.03%	0.04%	0.03%	0.03%	0.03%
Supplemental Data:					
Net assets, end of period (000 omitted)	\$11,947	\$31,147	\$35,306	\$41,483	\$50,468
Portfolio turnover ⁵	25%	34%	38%	42%	33%

- Per share numbers have been calculated using the average shares method.*
- Based on net asset value, which does not reflect the sales charge, redemption fee or contingent deferred sales charge, if applicable.*
- Amount does not reflect net expenses incurred by investment companies in which the Fund may invest.*
- This expense decrease is reflected in both the net expense and the net investment income (loss) ratios shown above. Amount does not reflect expense waiver/reimbursement recorded by investment companies in which the Fund may invest.*
- Securities that mature are considered sales for purposes of this calculation.*

See Notes which are an integral part of the Financial Statements

Financial Highlights – Class C Shares

(For a Share Outstanding Throughout Each Period)

	Year Ended October 31,				
	2022	2021	2020	2019	2018
Net Asset Value, Beginning of Period	\$5.81	\$5.22	\$4.99	\$4.99	\$5.14
Income From Investment Operations:					
Net investment income (loss) ¹	(0.06)	(0.11)	(0.09)	(0.06)	(0.08)
Net realized and unrealized gain (loss)	(1.67)	1.20	1.02	0.86	0.59
TOTAL FROM INVESTMENT OPERATIONS	(1.73)	1.09	0.93	0.80	0.51
Less Distributions:					
Distributions from net realized gain	(0.65)	(0.50)	(0.70)	(0.80)	(0.66)
Net Asset Value, End of Period	\$3.43	\$5.81	\$5.22	\$4.99	\$4.99
Total Return²	(32.74)%	21.80%	20.96%	18.69%	11.36%
Ratios to Average Net Assets:					
Net expenses ³	2.45%	2.42%	2.44%	2.45%	2.46%
Net investment income (loss)	(1.60)%	(1.92)%	(1.87)%	(1.31)%	(1.56)%
Expense waiver/reimbursement ⁴	0.03%	0.04%	0.03%	0.03%	0.03%
Supplemental Data:					
Net assets, end of period (000 omitted)	\$64,766	\$139,690	\$141,074	\$135,883	\$144,284
Portfolio turnover ⁵	25%	34%	38%	42%	33%

- Per share numbers have been calculated using the average shares method.*
- Based on net asset value, which does not reflect the sales charge, redemption fee or contingent deferred sales charge, if applicable.*
- Amount does not reflect net expenses incurred by investment companies in which the Fund may invest.*
- This expense decrease is reflected in both the net expense and the net investment income (loss) ratios shown above. Amount does not reflect expense waiver/reimbursement recorded by investment companies in which the Fund may invest.*
- Securities that mature are considered sales for purposes of this calculation.*

See Notes which are an integral part of the Financial Statements

Financial Highlights – Class R Shares

(For a Share Outstanding Throughout Each Period)

	Year Ended October 31,				
	2022	2021	2020	2019	2018
Net Asset Value, Beginning of Period	\$7.79	\$6.82	\$6.28	\$6.04	\$6.07
Income From Investment Operations:					
Net investment income (loss) ¹	(0.06)	(0.11)	(0.09)	(0.05)	(0.06)
Net realized and unrealized gain (loss)	(2.29)	1.58	1.33	1.09	0.69
TOTAL FROM INVESTMENT OPERATIONS	(2.35)	1.47	1.24	1.04	0.63
Less Distributions:					
Distributions from net realized gain	(0.65)	(0.50)	(0.70)	(0.80)	(0.66)
Net Asset Value, End of Period	\$4.79	\$7.79	\$6.82	\$6.28	\$6.04
Total Return²	(32.34)%	22.30%	21.64%	19.48%	11.62%

Ratios to Average Net Assets:

Net expenses ³	1.95%	1.95%	1.95%	1.95%	1.95%
Net investment income (loss)	(1.10)%	(1.45)%	(1.40)%	(0.81)%	(1.03)%
Expense waiver/reimbursement ⁴	0.27%	0.25%	0.25%	0.26%	0.27%

Supplemental Data:

Net assets, end of period (000 omitted)	\$3,428,775	\$5,582,064	\$4,848,579	\$4,313,852	\$3,877,851
Portfolio turnover ⁵	25%	34%	38%	42%	33%

- Per share numbers have been calculated using the average shares method.*
- Based on net asset value.*
- Amount does not reflect net expenses incurred by investment companies in which the Fund may invest.*
- This expense decrease is reflected in both the net expense and the net investment income (loss) ratios shown above. Amount does not reflect expense waiver/reimbursement recorded by investment companies in which the Fund may invest.*
- Securities that mature are considered sales for purposes of this calculation.*

See Notes which are an integral part of the Financial Statements

Financial Highlights – Institutional Shares

(For a Share Outstanding Throughout Each Period)

	Year Ended October 31,				
	2022	2021	2020	2019	2018
Net Asset Value, Beginning of Period	\$8.03	\$6.98	\$6.39	\$6.11	\$6.10
Income From Investment Operations:					
Net investment income (loss) ¹	(0.03)	(0.07)	(0.06)	(0.02)	(0.03)
Net realized and unrealized gain (loss)	(2.37)	1.62	1.35	1.10	0.70
TOTAL FROM INVESTMENT OPERATIONS	(2.40)	1.55	1.29	1.08	0.67
Less Distributions:					
Distributions from net realized gain	(0.65)	(0.50)	(0.70)	(0.80)	(0.66)
Net Asset Value, End of Period	\$4.98	\$8.03	\$6.98	\$6.39	\$6.11
Total Return²	(31.97)%	22.96%	22.11%	19.98%	12.29%
Ratios to Average Net Assets:					
Net expenses ³	1.44%	1.42%	1.44%	1.45%	1.46%
Net investment income (loss)	(0.60)%	(0.92)%	(0.89)%	(0.31)%	(0.52)%
Expense waiver/reimbursement ⁴	0.03%	0.04%	0.03%	0.03%	0.03%
Supplemental Data:					
Net assets, end of period (000 omitted)	\$390,516	\$808,904	\$640,411	\$452,014	\$325,596
Portfolio turnover ⁵	25%	34%	38%	42%	33%

- Per share numbers have been calculated using the average shares method.*
- Based on net asset value.*
- Amount does not reflect net expenses incurred by investment companies in which the Fund may invest.*
- This expense decrease is reflected in both the net expense and the net investment income (loss) ratios shown above. Amount does not reflect expense waiver/reimbursement recorded by investment companies in which the Fund may invest.*
- Securities that mature are considered sales for purposes of this calculation.*

See Notes which are an integral part of the Financial Statements

Statement of Assets and Liabilities

October 31, 2022

Assets:

Investment in securities, at value including \$140,640,117 of securities loaned and \$896,490,723 of investments in affiliated holdings and \$618,626,218 of investments in affiliated companies* (identified cost \$3,716,566,089)	\$5,243,855,413
Cash	1,382,089
Cash denominated in foreign currencies (identified cost \$51,885)	48,375
Income receivable	1,715,637
Income receivable from affiliated holdings	1,940,634
Receivable for investments sold	2,379,549
Receivable for shares sold	667,092
TOTAL ASSETS	5,251,988,789

Liabilities:

Payable for investments purchased	2,797,328
Payable for shares redeemed	4,436,373
Payable for collateral due to broker for securities lending (Note 2)	147,703,796
Payable for investment adviser fee (Note 5)	176,574
Payable for administrative fee (Note 5)	10,992
Payable for Directors'/Trustees' fees (Note 5)	4,585
Payable for distribution services fee (Note 5)	1,071,622
Payable for other service fees (Notes 2 and 5)	2,471,594
Accrued expenses (Note 5)	860,673
TOTAL LIABILITIES	159,533,537

Net assets for 1,067,558,841 shares outstanding	\$5,092,455,252
---	-----------------

Net Assets Consist of:

Paid-in capital	\$3,648,565,887
Total distributable earnings (loss)	1,443,889,365
TOTAL NET ASSETS	\$5,092,455,252

Statement of Assets and Liabilities – continued

Net Asset Value, Offering Price and Redemption Proceeds Per Share:

Class A Shares:

Net asset value per share (\$1,196,452,650 ÷ 250,580,960 shares outstanding), no par value, unlimited shares authorized	\$	4.77
Offering price per share (100/94.50 of \$4.77)	\$	5.05
Redemption proceeds per share	\$	4.77

Class B Shares:

Net asset value per share (\$11,946,661 ÷ 3,469,695 shares outstanding), no par value, unlimited shares authorized	\$	3.44
Offering price per share	\$	3.44
Redemption proceeds per share (94.50/100 of \$3.44)	\$	3.25

Class C Shares:

Net asset value per share (\$64,765,694 ÷ 18,870,624 shares outstanding), no par value, unlimited shares authorized	\$	3.43
Offering price per share	\$	3.43
Redemption proceeds per share (99.00/100 of \$3.43)	\$	3.40

Class R Shares:

Net asset value per share (\$3,428,774,517 ÷ 716,221,444 shares outstanding), no par value, unlimited shares authorized	\$	4.79
Offering price per share	\$	4.79
Redemption proceeds per share	\$	4.79

Institutional Shares:

Net asset value per share (\$390,515,730 ÷ 78,416,118 shares outstanding), no par value, unlimited shares authorized	\$	4.98
Offering price per share	\$	4.98
Redemption proceeds per share	\$	4.98

* See information listed after the Fund's Portfolio of Investments.

See Notes which are an integral part of the Financial Statements

Statement of Operations

Year Ended October 31, 2022

Investment Income:

Dividends (including \$6,895,377 received from affiliated holdings* and net of foreign taxes withheld of \$1,094,796)	\$ 51,013,647
Net income on securities loaned (includes \$1,158,819 earned from affiliated holdings related to cash collateral balances) (Note 2)	908,520
Interest	847,465
TOTAL INCOME	52,769,632

Expenses:

Investment adviser fee (Note 5)	79,613,334
Administrative fee (Note 5)	4,823,182
Custodian fees	415,222
Transfer agent fees (Note 2)	5,081,775
Directors'/Trustees' fees (Note 5)	43,355
Auditing fees	43,099
Legal fees	10,012
Portfolio accounting fees	214,083
Distribution services fee (Note 5)	24,776,642
Other service fees (Notes 2 and 5)	14,005,040
Share registration costs	100,019
Printing and postage	229,964
Miscellaneous (Note 5)	72,356
TOTAL EXPENSES	129,428,083

Waivers and Reimbursement:

Waiver/reimbursement of investment adviser fee (Note 5)	(1,635,255)
Waiver of other operating expenses (Note 5)	(9,721,908)
TOTAL WAIVERS AND REIMBURSEMENT	(11,357,163)
Net expenses	118,070,920
Net investment income (loss)	(65,301,288)

Statement of Operations – continued

Realized and Unrealized Gain (Loss) on Investments and Foreign Currency Transactions:

Net realized loss on investments (including foreign taxes withheld of \$(708,080) and (including net realized loss of \$(147,072,009) on sales of investments in affiliated companies and holdings*)	\$ (10,731,277)
Net realized loss on foreign currency transactions	(31,245)
Realized gain distribution from affiliated investment company shares*	40,129
Net change in unrealized appreciation of investments (including net change in unrealized appreciation of \$(180,019,672) of investments in affiliated companies and holdings*)	(2,610,824,577)
Net change in unrealized appreciation/depreciation of translation of assets and liabilities in foreign currency	(11,884)
Net realized and unrealized gain (loss) on investments and foreign currency transactions	(2,621,558,854)
Change in net assets resulting from operations	\$(2,686,860,142)

* See information listed after the Fund's Portfolio of Investments.

See Notes which are an integral part of the Financial Statements

Statement of Changes in Net Assets

Year Ended October 31	2022	2021
Increase (Decrease) in Net Assets		
Operations:		
Net investment loss	\$ (65,301,288)	\$ (116,990,124)
Net realized gain (loss)	(10,722,393)	780,854,529
Net change in unrealized appreciation/depreciation	(2,610,836,461)	972,909,411
CHANGE IN NET ASSETS RESULTING FROM OPERATIONS	(2,686,860,142)	1,636,773,816
Distributions to Shareholders:		
Class A Shares	(169,659,986)	(132,230,914)
Class B Shares	(3,408,597)	(3,299,219)
Class C Shares	(15,505,345)	(13,420,138)
Class R Shares	(466,665,097)	(353,888,255)
Institutional Shares	(64,883,150)	(46,545,249)
CHANGE IN NET ASSETS RESULTING FROM DISTRIBUTIONS TO SHAREHOLDERS	(720,122,175)	(549,383,775)
Share Transactions:		
Proceeds from sale of shares	221,241,432	506,750,596
Net asset value of shares issued to shareholders in payment of distributions declared	673,227,029	484,330,943
Cost of shares redeemed	(980,412,406)	(967,176,209)
CHANGE IN NET ASSETS RESULTING FROM SHARE TRANSACTIONS	(85,943,945)	23,905,330
Change in net assets	(3,492,926,262)	1,111,295,371
Net Assets:		
Beginning of period	8,585,381,514	7,474,086,143
End of period	\$ 5,092,455,252	\$8,585,381,514

See Notes which are an integral part of the Financial Statements

Notes to Financial Statements

October 31, 2022

1. ORGANIZATION

Federated Hermes Equity Funds (the "Trust") is registered under the Investment Company Act of 1940, as amended (the "Act"), as an open-end management investment company. The Trust consists of eight portfolios. The financial statements included herein are only those of Federated Hermes Kaufmann Fund (the "Fund"), a diversified portfolio. The financial statements of the other portfolios are presented separately. The assets of each portfolio are segregated and a shareholder's interest is limited to the portfolio in which shares are held. Each portfolio pays its own expenses. The Fund offers five classes of shares: Class A Shares, Class B Shares, Class C Shares, Class R Shares and Institutional Shares. All shares of the Fund have equal rights with respect to voting, except on class-specific matters. The investment objective of the Fund is to provide capital appreciation.

Class B Shares may be purchased through an exchange from the same share class of another Federated Hermes fund but are closed to new accounts, new investors and new purchases made by existing shareholders (excluding reinvestment of dividends and capital gains). Class B Shares of the Fund may be exchanged for Class B Shares of any other Federated Hermes fund.

2. SIGNIFICANT ACCOUNTING POLICIES

The following is a summary of significant accounting policies consistently followed by the Fund in the preparation of its financial statements. These policies are in conformity with U.S. generally accepted accounting principles (GAAP).

Investment Valuation

In calculating its net asset value (NAV), the Fund generally values investments as follows:

- Equity securities listed on an exchange or traded through a regulated market system are valued at their last reported sale price or official closing price in their principal exchange or market.
- Shares of other mutual funds or non-exchange-traded investment companies are valued based upon their reported NAVs, or NAV per share practical expedient, as applicable.
- Fixed-income securities are fair valued using price evaluations provided by a pricing service approved by Federated Equity Management Company of Pennsylvania (the "Adviser").
- Derivative contracts listed on exchanges are valued at their reported settlement or closing price, except that options are valued at the mean of closing bid and ask quotations.
- Over-the-counter (OTC) derivative contracts are fair valued using price evaluations provided by a pricing service approved by the Adviser.
- For securities that are fair valued in accordance with procedures established by and under the general supervision of the Adviser, certain factors may be considered, such as: the last traded or purchase price of the security, information obtained by contacting the issuer or dealers, analysis of the issuer's financial statements or other available documents, fundamental analytical data, the nature and duration of restrictions on disposition, the movement of the market in which the security is

normally traded, public trading in similar securities or derivative contracts of the issuer or comparable issuers, movement of a relevant index, or other factors including but not limited to industry changes and relevant government actions.

If any price, quotation, price evaluation or other pricing source is not readily available when the NAV is calculated, if the Fund cannot obtain price evaluations from a pricing service or from more than one dealer for an investment within a reasonable period of time as set forth in the Adviser's valuation policies and procedures for the Fund, or if information furnished by a pricing service, in the opinion of the Adviser's valuation committee ("Valuation Committee"), is deemed not representative of the fair value of such security, the Fund uses the fair value of the investment determined in accordance with the procedures described below. There can be no assurance that the Fund could obtain the fair value assigned to an investment if it sold the investment at approximately the time at which the Fund determines its NAV per share, and the actual value obtained could be materially different.

Fair Valuation and Significant Events Procedures

Pursuant to Rule 2a-5 under the Act, the Trustees have designated the Adviser as the Fund's valuation designee to perform any fair value determinations for securities and other assets held by the Fund. The Adviser is subject to the Trustees' oversight and certain reporting and other requirements intended to provide the Trustees the information needed to oversee the Adviser's fair value determinations.

The Adviser, acting through its Valuation Committee, is responsible for determining the fair value of investments for which market quotations are not readily available. The Valuation Committee is comprised of officers of the Adviser and certain of the Adviser's affiliated companies and determines fair value and oversees the calculation of the NAV. The Valuation Committee is also authorized to use pricing services to provide fair value evaluations of the current value of certain investments for purposes of calculating the NAV. The Valuation Committee employs various methods for reviewing third-party pricing-service evaluations including periodic reviews of third-party pricing services' policies, procedures and valuation methods (including key inputs, methods, models and assumptions), transactional back-testing, comparisons of evaluations of different pricing services, and review of price challenges by the Adviser based on recent market activity. In the event that market quotations and price evaluations are not available for an investment, the Valuation Committee determines the fair value of the investment in accordance with procedures adopted by the Adviser. The Trustees periodically review the fair valuations made by the Valuation Committee. The Trustees have also approved the Adviser's fair valuation and significant events procedures as part of the Fund's compliance program and will review any changes made to the procedures.

Factors considered by pricing services in evaluating an investment include the yields or prices of investments of comparable quality, coupon, maturity, call rights and other potential prepayments, terms and type, reported transactions, indications as to values from dealers and general market conditions. Some pricing services provide a single price evaluation reflecting the bid-side of the market for an investment (a "bid" evaluation). Other pricing services offer both bid evaluations and price evaluations indicative of a price between the prices bid and ask for the investment (a "mid" evaluation). The Fund normally uses bid evaluations for any U.S. Treasury and Agency securities, mortgage-backed securities and municipal securities. The Fund normally uses

mid evaluations for any other types of fixed-income securities and any OTC derivative contracts. In the event that market quotations and price evaluations are not available for an investment, the fair value of the investment is determined in accordance with procedures adopted by the Adviser.

The Adviser has also adopted procedures requiring an investment to be priced at its fair value whenever the Valuation Committee determines that a significant event affecting the value of the investment has occurred between the time as of which the price of the investment would otherwise be determined and the time as of which the NAV is computed. An event is considered significant if there is both an affirmative expectation that the investment's value will change in response to the event and a reasonable basis for quantifying the resulting change in value. Examples of significant events that may occur after the close of the principal market on which a security is traded, or after the time of a price evaluation provided by a pricing service or a dealer, include:

- With respect to securities traded principally in foreign markets, significant trends in U.S. equity markets or in the trading of foreign securities index futures contracts;
- Political or other developments affecting the economy or markets in which an issuer conducts its operations or its securities are traded;
- Announcements concerning matters such as acquisitions, recapitalizations, litigation developments, or a natural disaster affecting the issuer's operations or regulatory changes or market developments affecting the issuer's industry.

The Adviser has adopted procedures whereby the Valuation Committee uses a pricing service to provide factors to update the fair value of equity securities traded principally in foreign markets from the time of the close of their respective foreign stock exchanges to the pricing time of the Fund. For other significant events, the Fund may seek to obtain more current quotations or price evaluations from alternative pricing sources. If a reliable alternative pricing source is not available, the Valuation Committee will determine the fair value of the investment in accordance with the fair valuation procedures approved by the Adviser. The Trustees periodically review fair valuations made in response to significant events.

Repurchase Agreements

The Fund may invest in repurchase agreements for short-term liquidity purposes. It is the policy of the Fund to require the other party to a repurchase agreement to transfer to the Fund's custodian or sub-custodian eligible securities or cash with a market value (after transaction costs) at least equal to the repurchase price to be paid under the repurchase agreement. The eligible securities are transferred to accounts with the custodian or sub-custodian in which the Fund holds a "securities entitlement" and exercises "control" as those terms are defined in the Uniform Commercial Code. The Fund has established procedures for monitoring the market value of the transferred securities and requiring the transfer of additional eligible securities if necessary to equal at least the repurchase price. These procedures also allow the other party to require securities to be transferred from the account to the extent that their market value exceeds the repurchase price or in exchange for other eligible securities of equivalent market value.

The insolvency of the other party or other failure to repurchase the securities may delay the disposition of the underlying securities or cause the Fund to receive less than the full repurchase price. Under the terms of the repurchase agreement, any amounts received by the Fund in excess of the repurchase price and related transaction costs must be remitted to the other party.

The Fund may enter into repurchase agreements in which eligible securities are transferred into joint trading accounts maintained by the custodian or sub-custodian for investment companies and other clients advised by the Fund's Adviser and its affiliates. The Fund will participate on a pro rata basis with the other investment companies and clients in its share of the securities transferred under such repurchase agreements and in its share of proceeds from any repurchase or other disposition of such securities.

Investment Income, Gains and Losses, Expenses and Distributions

Investment transactions are accounted for on a trade-date basis. Realized gains and losses from investment transactions are recorded on an identified-cost basis. Interest income and expenses are accrued daily. Dividend income and distributions to shareholders are recorded on the ex-dividend date. Foreign dividends are recorded on the ex-dividend date or when the Fund is informed of the ex-dividend date. Distributions of net investment income, if any, are declared and paid annually. Non-cash dividends included in dividend income, if any, are recorded at fair value. Amortization/accretion of premium and discount is included in investment income. Investment income, realized and unrealized gains and losses, and certain fund-level expenses are allocated to each class based on relative average daily net assets, except that select classes will bear certain expenses unique to those classes. Dividends are declared separately for each class. No class has preferential dividend rights; differences in per share dividend rates are generally due to differences in separate class expenses. The detail of the total fund expense waivers and reimbursement of \$11,357,163 is disclosed in Note 5.

Transfer Agent Fees

For the year ended October 31, 2022, transfer agent fees for the Fund were as follows:

	Transfer Agent Fees Incurred
Class A Shares	\$1,201,389
Class B Shares	15,182
Class C Shares	74,364
Class R Shares	3,356,814
Institutional Shares	434,026
TOTAL	\$5,081,775

Other Service Fees

The Fund may pay other service fees up to 0.25% of the average daily net assets of the Fund's Class A Shares, Class B Shares, Class C Shares and Class R Shares to unaffiliated financial intermediaries or to Federated Shareholder Services Company (FSSC) for providing services to shareholders and maintaining shareholder accounts. Subject to the terms described in the Expense Limitation note, FSSC may voluntarily reimburse the Fund for other service fees.

For the year ended October 31, 2022, other service fees for the Fund were as follows:

	Other Service Fees Incurred
Class A Shares	\$ 3,629,157
Class B Shares	46,510
Class C Shares	226,571
Class R Shares	10,102,802
TOTAL	\$14,005,040

Federal Taxes

It is the Fund's policy to comply with the Subchapter M provision of the Internal Revenue Code and to distribute to shareholders each year substantially all of its income. Accordingly, no provision for federal income tax is necessary. As of and during the year ended October 31, 2022, the Fund did not have a liability for any uncertain tax positions. The Fund recognizes interest and penalties, if any, related to tax liabilities as income tax expense in the Statement of Operations. As of October 31, 2022, tax years 2019 through 2022 remain subject to examination by the Fund's major tax jurisdictions, which include the United States of America and the Commonwealth of Massachusetts.

The Fund may be subject to taxes imposed by governments of countries in which it invests. Such taxes are generally based on either income or gains earned or repatriated. The Fund accrues and applies such taxes to net investment income, net realized gains and net unrealized gains as income and/or gains are earned.

When-Issued and Delayed-Delivery Transactions

The Fund may engage in when-issued or delayed-delivery transactions. The Fund records when-issued securities on the trade date and maintains security positions such that sufficient liquid assets will be available to make payment for the securities purchased. Securities purchased on a when-issued or delayed-delivery basis are marked to market daily and begin earning interest on the settlement date. Losses may occur on these transactions due to changes in market conditions or the failure of counterparties to perform under the contract.

Futures Contracts

The Fund purchases and sells financial futures contracts to manage cash flows and duration, enhance yield and to potentially reduce transaction costs. Upon entering into a financial futures contract with a broker, the Fund is required to deposit with a broker, either U.S. government securities or a specified amount of cash, which is shown as due from broker in the Statement of Assets and Liabilities. Futures contracts are valued daily and unrealized gains or losses are recorded in a "variation margin" account. The Fund receives from or pays to the broker a specified amount of cash based upon changes in the variation margin account. When a contract is closed, the Fund recognizes a realized gain or loss. Futures contracts have market risks, including the risk that the change in the value of the contract may not correlate with the changes in the value of the underlying securities. There is minimal counterparty risk to the Fund since futures contracts are exchange traded and the exchange's clearing house, as counterparty to all exchange traded futures contracts, guarantees the futures contracts against default.

During the year ended October 31, 2022, the Fund held no futures contracts.

Foreign Currency Translation

The accounting records of the Fund are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the rates of exchange of such currencies against U.S. dollars on the date of valuation. Purchases and sales of securities, income and expenses are translated at the rate of exchange quoted on the respective date that such transactions are recorded. The Fund does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. Such fluctuations are included with the net realized and unrealized gain or loss from investments.

Reported net realized foreign exchange gains or losses arise from sales of foreign currencies, currency gains or losses realized between the trade and settlement dates on securities transactions, the difference between the amounts of dividends, interest and foreign withholding taxes recorded on the Fund's books, and the U.S. dollar equivalent of the amounts actually received or paid. Net unrealized foreign exchange gains and losses arise from changes in the value of assets and liabilities other than investments in securities at period end, resulting from changes in the exchange rate.

Securities Lending

The Fund participates in a securities lending program providing for the lending of equity securities to qualified brokers. The term of the loans within the program is one year or less. The Fund normally receives cash collateral for securities loaned that may be invested in affiliated money market funds, other money market instruments and/or repurchase agreements. Investments in money market funds may include funds with a "floating" NAV that can impose redemption fees and liquidity gates, impose certain operational impediments to investing cash collateral, and, if the investee fund's NAV decreases, result in the Fund recognizing losses and being required to cover the decrease in the value of the cash collateral. Collateral is maintained at a minimum level of 100% of the market value of investments loaned, plus interest, if applicable. Earnings on collateral are allocated between the borrower of the security, the securities lending agent, as a fee for its services under the program and the Fund, according to agreed-upon rates. The Fund will not have the right to vote on securities while they are on loan. However, the Fund will attempt to terminate a loan in an effort to reacquire the securities in time to vote on matters that are deemed to be material by the Adviser. There can be no assurance that the Fund will have sufficient notice of such matters to be able to terminate the loan in time to vote thereon.

Securities lending transactions are subject to Master Netting Agreements which are agreements between the Fund and its counterparties that provide for the net settlement of all transactions and collateral with the Fund, through a single payment, in the event of default or termination. Amounts presented on the Portfolio of Investments and Statement of Assets and Liabilities are not net settlement amounts but gross. As indicated below, the cash collateral received by the Fund exceeds the market value of the securities loaned reducing the net settlement amount to zero. The chart below

identifies the amount of collateral received as well as the market value of securities on loan. Additionally, the securities lending agreement executed by the Fund includes an indemnification clause. This clause stipulates that the borrower will reimburse the Fund for any losses as a result of any failure of the borrower to return equivalent securities to the Fund.

As of October 31, 2022, securities subject to this type of arrangement and related collateral were as follows:

Market Value of Securities Loaned	Collateral Received
\$140,640,117	\$147,703,796

Restricted Securities

The Fund may purchase securities which are considered restricted. Restricted securities are securities that either: (a) cannot be offered for public sale without first being registered, or being able to take advantage of an exemption from registration, under the Securities Act of 1933; or (b) are subject to contractual restrictions on public sales. In some cases, when a security cannot be offered for public sale without first being registered, the issuer of the restricted security has agreed to register such securities for resale, at the issuer's expense, either upon demand by the Fund or in connection with another registered offering of the securities. Many such restricted securities may be resold in the secondary market in transactions exempt from registration. Restricted securities may be determined to be liquid under criteria established by the Trustees. The Fund will not incur any registration costs upon such resales. The Fund's restricted securities, like other securities, are priced in accordance with procedures established by and under the general supervision of the Adviser.

Additional information on restricted securities held at October 31, 2022, is as follows:

Security	Acquisition Date	Cost	Value
Agnico Eagle Mines Ltd.	12/26/2018	\$47,282,195	\$50,554,000
Apollo Investment Fund V	5/18/2001	\$ 0	\$ 83,588
Expand Networks Ltd.	9/22/2000	\$ 2,500,000	\$ 0
FA Private Equity Fund IV LP	3/4/2002	\$ 0	\$ 342,495
Latin Healthcare Fund	11/28/2000	\$ 0	\$ 268,383
Multiplex, Inc., Pfd., Series C	2/22/2001	\$ 5,000,001	\$ 0
Sensible Technologies, Inc.	10/15/2004	\$ 0	\$ 0

Other

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets, liabilities, expenses and revenues reported in the financial statements. Actual results could differ materially from those estimated. The Fund applies investment company accounting and reporting guidance.

3. SHARES OF BENEFICIAL INTEREST

The following tables summarize share activity:

Class A Shares:	Year Ended 10/31/2022		Year Ended 10/31/2021	
	Shares	Amount	Shares	Amount
Shares sold	11,778,642	\$ 66,443,588	15,067,037	\$ 109,479,435
Shares issued to shareholders in payment of distributions declared	24,571,531	159,712,501	17,650,372	124,435,121
Shares redeemed	(46,267,489)	(246,619,737)	(38,204,058)	(280,361,852)
NET CHANGE RESULTING FROM CLASS A SHARE TRANSACTIONS	(9,917,316)	\$ (20,463,648)	(5,486,649)	\$ (46,447,296)

Class B Shares:	Year Ended 10/31/2022		Year Ended 10/31/2021	
	Shares	Amount	Shares	Amount
Shares sold	35,296	\$ 142,413	39,714	\$ 219,298
Shares issued to shareholders in payment of distributions declared	691,871	3,258,712	598,462	3,177,833
Shares redeemed	(2,603,391)	(10,390,549)	(2,034,324)	(11,230,539)
NET CHANGE RESULTING FROM CLASS B SHARE TRANSACTIONS	(1,876,224)	\$ (6,989,424)	(1,396,148)	\$ (7,833,408)

Class C Shares:	Year Ended 10/31/2022		Year Ended 10/31/2021	
	Shares	Amount	Shares	Amount
Shares sold	1,932,137	\$ 7,789,685	3,357,830	\$ 18,375,189
Shares issued to shareholders in payment of distributions declared	3,146,586	14,788,954	2,425,908	12,857,313
Shares redeemed	(10,257,512)	(39,840,351)	(8,749,851)	(47,655,601)
NET CHANGE RESULTING FROM CLASS C SHARE TRANSACTIONS	(5,178,789)	\$ (17,261,712)	(2,966,113)	\$ (16,423,099)

Class R Shares:	Year Ended 10/31/2022		Year Ended 10/31/2021	
	Shares	Amount	Shares	Amount
Shares sold	9,866,978	\$ 54,978,935	16,408,632	\$ 118,973,341
Shares issued to shareholders in payment of distributions declared	66,633,625	434,451,065	42,729,473	302,097,374
Shares redeemed	(77,124,359)	(417,451,381)	(53,457,965)	(393,343,125)
NET CHANGE RESULTING FROM CLASS R SHARE TRANSACTIONS	(623,756)	\$ 71,978,619	5,680,140	\$ 27,727,590

Institutional Shares:	Year Ended 10/31/2022		Year Ended 10/31/2021	
	Shares	Amount	Shares	Amount
Shares sold	16,069,132	\$ 91,886,811	34,363,850	\$ 259,703,333
Shares issued to shareholders in payment of distributions declared	9,039,377	61,015,797	5,752,521	41,763,302
Shares redeemed	(47,370,755)	(266,110,388)	(31,124,767)	(234,585,092)
NET CHANGE RESULTING FROM INSTITUTIONAL SHARE TRANSACTIONS	(22,262,246)	\$(113,207,780)	8,991,604	\$ 66,881,543
NET CHANGE RESULTING FROM TOTAL FUND SHARE TRANSACTIONS	(39,858,331)	\$(85,943,945)	4,822,834	\$ 23,905,330

Redemption Fees

Effective January 1, 2021, the redemption fee for the Fund's Class R Shares was eliminated. Prior to January 1, 2021, the Fund's Class R Shares imposed a redemption fee of 0.20% on the redemption price of the Fund's Class R Shares redeemed, if such shares were purchased after February 1, 1985. The redemption fee was applied to the Fund's Class R Shares expenses for providing redemption services, including, but not limited to: transfer agent fees, postage, printing, telephone and related employment costs. Excess fee proceeds, if any, were added to the Fund's assets. Shares acquired through employer-sponsored retirement plans were not subject to the redemption fee. However, if shares were purchased for a retirement plan account through a broker, financial institution or other intermediary maintaining an omnibus account for the shares, the waiver may not have applied. In addition, this waiver did not apply to individual retirement accounts, such as Traditional, Roth and SEP-IRAs. For the year ended October 31, 2021, redemption fees of \$112,812, were allocated to cover the cost of redemptions.

4. FEDERAL TAX INFORMATION

The accounting treatment of certain items in accordance with income tax regulations may differ from the accounting treatment in accordance with GAAP which may result in permanent differences. In the case of the Fund, such differences primarily result from net operating losses.

For the year ended October 31, 2022, permanent differences identified and reclassified among the components of net assets were as follows:

	Increase (Decrease)	Total Distributable Earnings (Loss)
Paid-In Capital		
\$(125,734,772)		\$125,734,772

The tax character of distributions as reported on the Statement of Changes in Net Assets for the years ended October 31, 2022 and 2021, was as follows:

	2022	2021
Long-term capital gains	\$720,122,175	\$549,383,775

As of October 31, 2022, the components of distributable earnings on a tax-basis were as follows:

Net unrealized appreciation	\$1,507,020,154
Capital loss carryforwards and deferrals	\$ (63,130,789)

The difference between book-basis and tax-basis net unrealized appreciation is attributable to differing treatments for deferral of losses on wash sales, discount accretion/premium amortization on debt securities, partnership adjustments, and passive foreign investment company adjustments.

At October 31, 2022, the cost of investments for federal tax purposes was \$3,736,818,119. The net unrealized appreciation of investments for federal tax purposes was \$1,507,037,294. This consists of net unrealized appreciation from investments for those securities having an excess of value over cost of \$1,897,229,534 and net unrealized depreciation from investments for those securities having an excess of cost over value of \$390,192,240.

As of October 31, 2022, the Fund had a capital loss carryforward of \$12,547,649 which will reduce the Fund's taxable income arising from future net realized gains on investments, if any, to the extent permitted by the Code, thereby reducing the amount of distributions to shareholders which would otherwise be necessary to relieve the Fund of any liability for federal income tax. Pursuant to the Code, these net capital losses retain their character as either short-term or long-term and do not expire.

The following schedule summarizes the Fund's capital loss carryforwards:

Short-Term	Long-Term	Total
\$—	\$12,547,649	\$12,547,649

Under current tax rules, a late-year ordinary loss may be deferred, in whole or in part, and treated as occurring on the first day of the following fiscal year. As of October 31, 2022, for federal income tax purposes, a late year ordinary loss of \$50,583,140 was deferred to November 1, 2022.

5. INVESTMENT ADVISER FEE AND OTHER TRANSACTIONS WITH AFFILIATES

Investment Adviser Fee

Effective July 1, 2022, the Fund's investment advisory contract provides for payment to the Adviser of an annual investment advisory fee based on the Fund's average daily net assets as shown in the chart below:

Assets Under Management	Investment Advisory Fee
Up to \$8 billion	1.275%
\$8 billion - \$9 billion	1.255%
\$9 billion - \$10 billion	1.235%
\$10 billion - \$12 billion	1.215%
Excess of \$12 billion	1.205%

Prior to July 1, 2022, the advisory agreement between the Fund and the Adviser provides for an annual fee equal to 1.30% of the Fund's average daily net assets. Pursuant to the settlement of certain litigation, the Adviser agreed, for a period continuing through June 30, 2022, to waive its investment advisory fee so that such fee will not exceed 1.275%. Also, as part of the settlement agreement, effective July 1, 2012 and continuing through June 30, 2022, the Adviser agreed to further waive the advisory fee by an additional 0.02%, 0.04%, 0.06% or 0.07% if the Fund's net assets exceed eight, nine, ten or twelve billion dollars, respectively. Subject to the terms described in the Expense Limitation note, the Adviser may voluntarily choose to waive any portion of its fee and/or reimburse certain operating expenses of the Fund for competitive reasons such as to maintain the Fund's expense ratio, or as and when appropriate, to maintain positive or zero net yields. For the year ended October 31, 2022, the Adviser voluntarily waived \$1,082,020 of its fee.

The Adviser has agreed to reimburse the Fund for certain investment adviser fees as a result of transactions in other affiliated investment companies. For the year ended October 31, 2022, the Adviser reimbursed \$553,235.

Certain of the Fund's assets are managed by Federated Global Investment Management Corp. (the "Sub-Adviser"). Under the terms of a sub-advisory agreement between the Adviser and the Sub-Adviser, the Sub-Adviser receives an allocable portion of the Fund's adviser fee. The fee is paid by the Adviser out of its resources and is not an incremental Fund expense. For the year ended October 31, 2022, the Sub-Adviser earned a fee of \$65,282,934.

Administrative Fee

Federated Administrative Services (FAS), under the Administrative Services Agreement, provides the Fund with administrative personnel and services. For purposes of determining the appropriate rate breakpoint, "Investment Complex" is defined as all of the Federated Hermes Funds subject to a fee under the Administrative Services Agreement. The fee paid to FAS is based on the average daily net assets of the Investment Complex as specified below:

Administrative Fee	Average Daily Net Assets of the Investment Complex
0.100%	on assets up to \$50 billion
0.075%	on assets over \$50 billion

Subject to the terms described in the Expense Limitation note, FAS may voluntarily choose to waive any portion of its fee. For the year ended October 31, 2022, the annualized fee paid to FAS was 0.078% of average daily net assets of the Fund.

In addition, FAS may charge certain out-of-pocket expenses to the Fund.

Distribution Services Fee

The Fund has adopted a Distribution Plan (the "Plan") pursuant to Rule 12b-1 under the Act. Under the terms of the Plan, the Fund will compensate Federated Securities Corp. (FSC), the principal distributor, from the daily net assets of the Fund's Class A Shares, Class B Shares, Class C Shares and Class R Shares to finance activities intended to result in the sale of these shares. The Plan provides that the Fund may incur distribution expenses at the following percentages of average daily net assets annually, to compensate FSC:

	Percentage of Average Daily Net Assets of Class
Class A Shares	0.25%
Class B Shares	0.75%
Class C Shares	0.75%
Class R Shares	0.50%

Subject to the terms described in the Expense Limitation note, FSC may voluntarily choose to waive any portion of its fee.

For the year ended October 31, 2022, distribution services fees for the Fund were as follows:

	Distribution Services Fees Incurred	Distribution Services Fees Waived
Class A Shares	\$ 3,639,193	\$ —
Class B Shares	139,531	—
Class C Shares	679,711	—
Class R Shares	20,318,207	(9,721,908)
TOTAL	\$24,776,642	\$(9,721,908)

When FSC receives fees, it may pay some or all of them to financial intermediaries whose customers purchase shares. For the year ended October 31, 2022, FSC retained \$13,653,668 of fees paid by the Fund.

Sales Charges

Front-end sales charges and contingent deferred sales charges (CDSC) do not represent expenses of the Fund. They are deducted from the proceeds of sales of Fund shares prior to investment or from redemption proceeds prior to remittance, as applicable. For the year ended October 31, 2022, FSC retained \$49,918 in sales charges from the sale of Class A Shares. FSC also retained \$1,579, \$7,464 and \$8,549 of CDSC relating to redemptions of Class A Shares, Class B Shares and Class C Shares, respectively.

Other Service Fees

For the year ended October 31, 2022, FSSC received \$7,231,512 of the other service fees disclosed in Note 2.

Commitments and Contingencies

In the course of pursuing its investment objective, the Fund may invest in limited partnerships and limited liability companies. These entities often require the Fund to commit to a total dollar amount to be invested. The actual investments are usually made in installments over a period of time. At October 31, 2022 the Fund had total commitments to limited partnerships and limited liability companies of \$35,957,452; of this amount, \$35,804,925 was actually invested by the Fund leaving the Fund contingently liable for additional investments of \$152,527.

Expense Limitation

The Adviser and certain of its affiliates (which may include FSC, FAS and FSSC) on their own initiative have agreed to waive certain amounts of their respective fees and/or reimburse expenses. Total annual fund operating expenses (as shown in the financial highlights, excluding dividends and other expenses related to short sales, interest expense, extraordinary expenses, tax reclaim recovery expenses and proxy-related expenses paid by the Fund, if any) paid by the Fund's Class A Shares, Class B Shares, Class C Shares, Class R Shares and Institutional Shares (after the voluntary waivers and/or reimbursements) will not exceed 1.95%, 2.50%, 2.50%, 1.95% and 1.50% (the "Fee Limit"), respectively, up to but not including the later of (the "Termination Date"): (a) January 1, 2024; or (b) the date of the Fund's next effective Prospectus. While the Adviser and its applicable affiliates currently do not anticipate terminating or increasing these arrangements prior to the Termination Date, these arrangements may only be terminated or the Fee Limit increased prior to the Termination Date with the agreement of the Trustees.

Interfund Transactions

During the year ended October 31, 2022, the Fund engaged in purchase and sale transactions with funds that have a common investment adviser (or affiliated investment advisers), common Directors/Trustees and/or common Officers. These purchase and sale transactions complied with Rule 17a-7 under the Act and amounted to \$5,236,598 and \$18,834,250, respectively. Net realized loss recognized on these transactions was \$4,959,384.

Directors'/Trustees' and Miscellaneous Fees

Certain Officers and Trustees of the Fund are Officers and Directors or Trustees of certain of the above companies. To efficiently facilitate payment, Independent Directors'/Trustees' fees and certain expenses related to conducting meetings of the Directors/Trustees and other miscellaneous expenses are paid by an affiliate of the Adviser which in due course are reimbursed by the Fund. These expenses related to conducting meetings of the Directors/Trustees and other miscellaneous expenses may be included in Accrued and Miscellaneous Expenses on the Statement of Assets and Liabilities and Statement of Operations, respectively.

6. INVESTMENT TRANSACTIONS

Purchases and sales of investments, excluding long-term U.S. government securities and short-term obligations, for the year ended October 31, 2022, were as follows:

Purchases	\$1,261,869,463
Sales	\$2,616,696,198

7. CONCENTRATION OF RISK

The Fund invests in securities of non-U.S. issuers. Political or economic developments may have an effect on the liquidity and volatility of portfolio securities and currency holdings.

At October 31, 2022, the diversification of countries was as follows:

Country	Percentage of Total Net Assets
United States	90.1%
Netherlands	6.4%
Canada	2.3%
Denmark	1.3%
Italy	0.8%
China	0.6%
Switzerland	0.6%
Belgium	0.2%
Brazil	0.2%
Israel	0.2%
Kampuchea, Democratic	0.2%
United Kingdom	0.1%

A substantial portion of the Fund's portfolio may be comprised of entities in the Health Care sector. As a result, the Fund may be more susceptible to any economic, business, political or other developments which generally affect these entities.

8. LINE OF CREDIT

The Fund participates with certain other Federated Hermes Funds, on a several basis, in an up to \$500,000,000 unsecured, 364-day, committed, revolving line of credit (LOC) agreement dated June 22, 2022. The LOC was made available to temporarily finance the repurchase or redemption of shares of the Fund, failed trades, payment of dividends, settlement of trades and for other short-term, temporary or emergency general business purposes. The Fund cannot borrow under the LOC if an inter-fund loan is outstanding. The Fund's ability to borrow under the LOC also is subject to the limitations of the Act and various conditions precedent that must be satisfied before the Fund can borrow. Loans under the LOC are charged interest at a fluctuating rate per annum equal to (a) the highest, on any day, of (i) the federal funds effective rate, (ii) the published secured overnight financing rate plus an assigned percentage, and (iii) 0.0%, plus (b) a margin. Any fund eligible to borrow under the LOC pays its pro rata share of a commitment fee based on the amount of the lenders' commitment that has not been utilized, quarterly in arrears and at maturity. As of October 31, 2022, the Fund had no outstanding loans. During the year ended October 31, 2022, the Fund did not utilize the LOC.

9. INTERFUND LENDING

Pursuant to an Exemptive Order issued by the Securities and Exchange Commission, the Fund, along with other funds advised by subsidiaries of Federated Hermes, Inc., may participate in an interfund lending program. This program provides an alternative credit facility allowing the Fund to borrow from other participating affiliated funds. As of October 31, 2022, there were no outstanding loans. During the year ended October 31, 2022, the program was not utilized.

10. INDEMNIFICATIONS

Under the Fund's organizational documents, its Officers and Directors/Trustees are indemnified against certain liabilities arising out of the performance of their duties to the Fund (other than liabilities arising out of their willful misfeasance, bad faith, gross negligence or reckless disregard of their duties to the Fund). In addition, in the normal course of business, the Fund provides certain indemnifications under arrangements with third parties. Typically, obligations to indemnify a third party arise in the context of an arrangement entered into by the Fund under which the Fund agrees to indemnify such third party for certain liabilities arising out of actions taken pursuant to the arrangement, provided the third party's actions are not deemed to have breached an agreed-upon standard of care (such as willful misfeasance, bad faith, gross negligence or reckless disregard of their duties under the contract). The Fund's maximum exposure under these arrangements is unknown as this would involve future claims that may be made against the Fund that have not yet arisen. The Fund does not anticipate any material claims or losses pursuant to these arrangements at this time, and accordingly expects the risk of loss to be remote.

11. OTHER MATTERS

An outbreak of respiratory disease caused by a novel coronavirus was first detected in China in late 2019 and subsequently spread globally. As of the date of the issuance of these financial statements, this coronavirus has resulted in, and may continue to result in, closed borders, enhanced health screenings, disruptions to healthcare service preparation and delivery, quarantines, cancellations, and disruptions to supply chains, workflow operations and consumer activity, as well as general concern and uncertainty. The impact of this coronavirus has resulted in substantial economic volatility. Health crises caused by outbreaks, such as the coronavirus outbreak, may exacerbate other pre-existing political, social and economic risks. The impact of this outbreak, and other epidemics and pandemics that may arise in the future, could continue to negatively affect the worldwide economy, as well as the economies of individual countries, individual companies (including certain Fund service providers and issuers of the Fund's investments) and the markets in general in significant and unforeseen ways. In addition, governments, their regulatory agencies, or self-regulatory organizations may take actions in response to the pandemic, including significant fiscal and monetary policy changes, that may affect the instruments in which the Fund invests or the issuers of such investments. Any such impact could adversely affect the Fund's performance.

12. SUBSEQUENT EVENT

On November 10, 2022, the Trustees approved a Plan of Conversion for the Class B Shares of the Fund pursuant to which the Class B Shares of the Fund will be converted into the Fund's existing Class A Shares on or about February 3, 2023, resulting in the closure and termination of the Fund's Class B Shares.

13. FEDERAL TAX INFORMATION (UNAUDITED)

For the year ended October 31, 2022, the amount of long-term capital gains designated by the Fund was \$720,122,175.

Report of Independent Registered Public Accounting Firm

TO THE BOARD OF TRUSTEES OF FEDERATED HERMES EQUITY FUNDS AND SHAREHOLDERS OF FEDERATED HERMES KAUFMANN FUND:

Opinion on the Financial Statements

We have audited the accompanying statement of assets and liabilities of Federated Hermes Kaufmann Fund (the “Fund”) (one of the portfolios constituting Federated Hermes Equity Funds (the “Trust”)), including the portfolio of investments, as of October 31, 2022, and the related statement of operations for the year then ended, the statement of changes in net assets for each of the two years in the period then ended, the financial highlights for each of the five years in the period then ended and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Fund (one of the portfolios constituting Federated Hermes Equity Funds) at October 31, 2022, the results of its operations for the year then ended, the changes in its net assets for each of the two years in the period then ended and its financial highlights for each of the five years in the period then ended, in conformity with U.S. generally accepted accounting principles.

Basis for Opinion

These financial statements are the responsibility of the Trust’s management. Our responsibility is to express an opinion on the Fund’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Trust in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements and financial highlights are free of material misstatement, whether due to error or fraud. The Trust is not required to have, nor were we engaged to perform, an audit of the Trust’s internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Trust’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our procedures included confirmation of securities owned as of October 31, 2022, by correspondence with the custodian, brokers, and others; when replies were not received from brokers or others, we performed other auditing procedures. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Ernst & Young LLP

We have served as the auditor of one or more Federated Hermes investment companies since 1979.

Boston, Massachusetts
December 23, 2022

Shareholder Expense Example (unaudited)

As a shareholder of the Fund, you incur two types of costs: (1) transaction costs, including sales charges (loads) on purchase or redemption payments; and (2) ongoing costs, including management fees and to the extent applicable, distribution (12b-1) fees and/or other service fees and other Fund expenses. This Example is intended to help you to understand your ongoing costs (in dollars) of investing in the Fund and to compare these costs with the ongoing costs of investing in other mutual funds. It is based on an investment of \$1,000 invested at the beginning of the period and held for the entire period from May 1, 2022 to October 31, 2022.

ACTUAL EXPENSES

The first section of the table below provides information about actual account values and actual expenses. You may use the information in this section, together with the amount you invested, to *estimate* the expenses that you incurred over the period. Simply divide your account value by \$1,000 (for example, an \$8,600 account value divided by \$1,000 = 8.6), then multiply the result by the number in the first section under the heading entitled “Expenses Paid During Period” to estimate the expenses attributable to your investment during this period.

HYPOTHETICAL EXAMPLE FOR COMPARISON PURPOSES

The second section of the table below provides information about hypothetical account values and hypothetical expenses based on the Fund’s actual expense ratio and an *assumed* rate of return of 5% per year before expenses, which is not the Fund’s actual return. Thus, you should *not* use the hypothetical account values and expenses to estimate the actual ending account balance or your expenses for the period. Rather, these figures are required to be provided to enable you to compare the ongoing costs of investing in the Fund with other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of the other funds.

Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transaction costs, such as sales charges (loads) on purchase or redemption payments. Therefore, the second section of the table is useful in comparing ongoing costs only, and will not help you determine the relative *total* costs of owning different funds. In addition, if these transaction costs were included, your costs would have been higher.

	Beginning Account Value 5/1/2022	Ending Account Value 10/31/2022	Expenses Paid During Period
Actual:			
Class A Shares	\$1,000	\$ 967.50	\$ 9.67
Class B Shares	\$1,000	\$ 963.60	\$12.13
Class C Shares	\$1,000	\$ 963.50	\$12.13
Class R Shares	\$1,000	\$ 967.70	\$ 9.67
Institutional Shares	\$1,000	\$ 970.80	\$ 7.20
Hypothetical (assuming a 5% return before expenses):			
Class A Shares	\$1,000	\$1,015.38	\$ 9.91
Class B Shares	\$1,000	\$1,012.85	\$12.43
Class C Shares	\$1,000	\$1,012.85	\$12.43
Class R Shares	\$1,000	\$1,015.38	\$ 9.91
Institutional Shares	\$1,000	\$1,017.90	\$ 7.38

1 Expenses are equal to the Fund's annualized net expense ratios, multiplied by the average account value over the period, multiplied by 184/365 (to reflect the one-half-year period). The annualized net expense ratios are as follows:

Class A Shares	1.95%
Class B Shares	2.45%
Class C Shares	2.45%
Class R Shares	1.95%
Institutional Shares	1.45%

Board of Trustees and Trust Officers

The Board of Trustees is responsible for managing the Trust business affairs and for exercising all the Trust powers except those reserved for the shareholders. The following tables give information about each Trustee and the senior officers of the Fund. Where required, the tables separately list Trustees who are “interested persons” of the Fund (i.e., “Interested” Trustees) and those who are not (i.e., “Independent” Trustees). Unless otherwise noted, the address of each person listed is 1001 Liberty Avenue, Pittsburgh, PA 15222-3779.

The address of all Independent Trustees listed is 4000 Ericsson Drive, Warrendale, PA 15086-7561; Attention: Mutual Fund Board. As of

December 31, 2021, the Trust comprised eight portfolio(s), and the Federated Hermes Fund Family consisted of 33 investment companies (comprising 102 portfolios). Unless otherwise noted, each Officer is elected annually.

Unless otherwise noted, each Trustee oversees all portfolios in the Federated Hermes Fund Family and serves for an indefinite term. The Fund’s Statement of Additional Information includes additional information about Trust Trustees and is available, without charge and upon request, by calling 1-800-341-7400, Option #4.

INTERESTED TRUSTEES BACKGROUND

Name	
Birth Date	
Positions Held with Trust	Principal Occupation(s) for Past Five Years,
Date Service Began	Other Directorships Held and Previous Position(s)
J. Christopher Donahue*	
Birth Date: April 11, 1949	
PRESIDENT AND TRUSTEE	
Indefinite Term	
Began serving: January 2000	
	Principal Occupations: Principal Executive Officer and President of certain of the Funds in the Federated Hermes Fund Family; Director or Trustee of the Funds in the Federated Hermes Fund Family; President, Chief Executive Officer and Director, Federated Hermes, Inc.; Chairman and Trustee, Federated Investment Management Company; Trustee, Federated Investment Counseling; Chairman and Director, Federated Global Investment Management Corp.; Chairman and Trustee, Federated Equity Management Company of Pennsylvania; Trustee, Federated Shareholder Services Company; Director, Federated Services Company.
	Previous Positions: President, Federated Investment Counseling; President and Chief Executive Officer, Federated Investment Management Company, Federated Global Investment Management Corp. and Passport Research, Ltd; Chairman, Passport Research, Ltd.

Name	Birth Date	Positions Held with Trust Date Service Began	Principal Occupation(s) for Past Five Years, Other Directorships Held and Previous Position(s)
John B. Fisher*	Birth Date: May 16, 1956	TRUSTEE Indefinite Term Began serving: May 2016	<p>Principal Occupations: Principal Executive Officer and President of certain of the Funds in the Federated Hermes Fund Family; Director or Trustee of certain of the Funds in the Federated Hermes Fund Family; Director and Vice President, Federated Hermes, Inc.; President, Director/Trustee and CEO, Federated Advisory Services Company, Federated Equity Management Company of Pennsylvania, Federated Global Investment Management Corp., Federated Investment Counseling, Federated Investment Management Company, and Federated MDTA LLC; Director, Federated Investors Trust Company.</p> <p>Previous Positions: President and Director of the Institutional Sales Division of Federated Securities Corp.; President and CEO of Passport Research, Ltd.; Director and President, Technology, Federated Services Company.</p>

* *Reasons for "interested" status: J. Christopher Donahue and John B. Fisher are interested due to their beneficial ownership of shares of Federated Hermes, Inc. and due to positions they hold with Federated Hermes, Inc. and its subsidiaries.*

INDEPENDENT TRUSTEES BACKGROUND

Name	Birth Date	Positions Held with Trust Date Service Began	Principal Occupation(s) for Past Five Years, Other Directorships Held, Previous Position(s) and Qualifications
John T. Collins	Birth Date: January 24, 1947	TRUSTEE Indefinite Term Began serving: October 2013	<p>Principal Occupations: Director or Trustee, and Chair of the Board of Directors or Trustees, of the Federated Hermes Fund Family; formerly, Chairman and CEO, The Collins Group, Inc. (a private equity firm) (Retired).</p> <p>Other Directorships Held: Director, KLX Energy Services Holdings, Inc. (oilfield services); former Director of KLX Corp. (aerospace).</p> <p>Qualifications: Mr. Collins has served in several business and financial management roles and directorship positions throughout his career. Mr. Collins previously served as Chairman and CEO of The Collins Group, Inc. (a private equity firm) and as a Director of KLX Corp. Mr. Collins serves as Chairman Emeriti, Bentley University. Mr. Collins previously served as Director and Audit Committee Member, Bank of America Corp.; Director, FleetBoston Financial Corp.; and Director, Beth Israel Deaconess Medical Center (Harvard University Affiliate Hospital).</p>

Name	Birth Date	Positions Held with Trust Date Service Began	Principal Occupation(s) for Past Five Years, Other Directorships Held, Previous Position(s) and Qualifications
G. Thomas Hough	Birth Date: February 28, 1955	TRUSTEE Indefinite Term Began serving: August 2015	<p>Principal Occupations: Director or Trustee, Chair of the Audit Committee of the Federated Hermes Fund Family; formerly, Vice Chair, Ernst & Young LLP (public accounting firm) (Retired).</p> <p>Other Directorships Held: Director, Chair of the Audit Committee, Equifax, Inc.; Lead Director, Member of the Audit and Nominating and Corporate Governance Committees, Haverty Furniture Companies, Inc.; formerly, Director, Member of Governance and Compensation Committees, Publix Super Markets, Inc.</p> <p>Qualifications: Mr. Hough has served in accounting, business management and directorship positions throughout his career. Mr. Hough most recently held the position of Americas Vice Chair of Assurance with Ernst & Young LLP (public accounting firm). Mr. Hough serves on the President's Cabinet and Business School Board of Visitors for the University of Alabama. Mr. Hough previously served on the Business School Board of Visitors for Wake Forest University, and he previously served as an Executive Committee member of the United States Golf Association.</p>
Maureen Lally-Green	Birth Date: July 5, 1949	TRUSTEE Indefinite Term Began serving: August 2009	<p>Principal Occupations: Director or Trustee of the Federated Hermes Fund Family; Adjunct Professor Emerita of Law, Duquesne University School of Law; formerly, Dean of the Duquesne University School of Law and Professor of Law and Interim Dean of the Duquesne University School of Law; formerly, Associate General Secretary and Director, Office of Church Relations, Diocese of Pittsburgh.</p> <p>Other Directorships Held: Director, CNX Resources Corporation (formerly known as CONSOL Energy Inc.).</p> <p>Qualifications: Judge Lally-Green has served in various legal and business roles and directorship positions throughout her career. Judge Lally-Green previously held the position of Dean of the School of Law of Duquesne University (as well as Interim Dean). Judge Lally-Green previously served as a member of the Superior Court of Pennsylvania and as a Professor of Law, Duquesne University School of Law. Judge Lally-Green was appointed by the Supreme Court of Pennsylvania to serve on the Supreme Court's Board of Continuing Judicial Education and the Supreme Court's Appellate Court Procedural Rules Committee. Judge Lally-Green also currently holds the positions on not for profit or for profit boards of directors as follows: Director and Chair, UPMC Mercy Hospital; Regent, Saint Vincent Seminary; Member, Pennsylvania State Board of Education (public); Director, Catholic Charities, Pittsburgh; and Director CNX Resources Corporation (formerly known as CONSOL Energy Inc.). Judge Lally-Green has held the positions of: Director, Auberle; Director, Epilepsy Foundation of Western and Central Pennsylvania; Director, Ireland Institute of Pittsburgh; Director, Saint Thomas More Society; Director and Chair, Catholic High Schools of the Diocese of Pittsburgh, Inc.; Director, Pennsylvania Bar Institute; Director, St. Vincent College; Director and Chair, North Catholic High School, Inc.; Director and Vice Chair, Our Campaign for the Church Alive!, Inc.; and Director, Saint Francis University.</p>

Name	Birth Date	Positions Held with Trust Date Service Began	Principal Occupation(s) for Past Five Years, Other Directorships Held, Previous Position(s) and Qualifications
Thomas M. O'Neill	Birth Date: June 14, 1951	TRUSTEE Indefinite Term Began serving: October 2006	<p>Principal Occupations: Director or Trustee of the Federated Hermes Fund Family; Sole Proprietor, Navigator Management Company (investment and strategic consulting).</p> <p>Other Directorships Held: None.</p> <p>Qualifications: Mr. O'Neill has served in several business, mutual fund and financial management roles and directorship positions throughout his career. Mr. O'Neill serves as Director, Medicines for Humanity. Mr. O'Neill previously served as Chief Executive Officer and President, Managing Director and Chief Investment Officer, Fleet Investment Advisors; President and Chief Executive Officer, Aeltus Investment Management, Inc.; General Partner, Hellman, Jordan Management Co., Boston, MA; Chief Investment Officer, The Putnam Companies, Boston, MA; Credit Analyst and Lending Officer, Fleet Bank; Director and Consultant, EZE Castle Software (investment order management software); Director, The Golisano Children's Museum of Naples, Florida; and Director, Midway Pacific (lumber).</p>
Madelyn A. Reilly	Birth Date: February 2, 1956	TRUSTEE Indefinite Term Began serving: November 2020	<p>Principal Occupations: Director or Trustee of the Federated Hermes Fund Family; formerly, Executive Vice President for Legal Affairs, General Counsel and Secretary to the Board of Directors, Duquesne University (Retired).</p> <p>Other Directorships Held: None.</p> <p>Qualifications: Ms. Reilly has served in various business and legal management roles throughout her career. Ms. Reilly previously served as Senior Vice President for Legal Affairs, General Counsel and Secretary to the Board of Directors and Assistant General Counsel and Director of Risk Management, Duquesne University. Prior to her work at Duquesne University, Ms. Reilly served as Assistant General Counsel of Compliance and Enterprise Risk as well as Senior Counsel of Environment, Health and Safety, PPG Industries. Ms. Reilly currently serves as a member of the Board of Directors of UPMC Mercy Hospital.</p>

Name	Birth Date	Positions Held with Trust Date Service Began	Principal Occupation(s) for Past Five Years, Other Directorships Held, Previous Position(s) and Qualifications
P. Jerome Richey	Birth Date: February 23, 1949	TRUSTEE Indefinite Term Began serving: October 2013	<p>Principal Occupations: Director or Trustee of the Federated Hermes Fund Family; Management Consultant; Retired; formerly, Senior Vice Chancellor and Chief Legal Officer, University of Pittsburgh and Executive Vice President and Chief Legal Officer, CONSOL Energy Inc. (now split into two separate publicly traded companies known as CONSOL Energy Inc. and CNX Resources Corp.).</p> <p>Other Directorships Held: None.</p> <p>Qualifications: Mr. Richey has served in several business and legal management roles and directorship positions throughout his career. Mr. Richey most recently held the positions of Senior Vice Chancellor and Chief Legal Officer, University of Pittsburgh. Mr. Richey previously served as Chairman of the Board, Epilepsy Foundation of Western Pennsylvania and Chairman of the Board, World Affairs Council of Pittsburgh. Mr. Richey previously served as Chief Legal Officer and Executive Vice President, CONSOL Energy Inc. and CNX Gas Company; and Board Member, Ethics Counsel and Shareholder, Buchanan Ingersoll & Rooney PC (a law firm).</p>
John S. Walsh	Birth Date: November 28, 1957	TRUSTEE Indefinite Term Began serving: January 1999	<p>Principal Occupations: Director or Trustee of the Federated Hermes Fund Family; President and Director, Heat Wagon, Inc. (manufacturer of construction temporary heaters); President and Director, Manufacturers Products, Inc. (distributor of portable construction heaters); President, Portable Heater Parts, a division of Manufacturers Products, Inc.</p> <p>Other Directorships Held: None.</p> <p>Qualifications: Mr. Walsh has served in several business management roles and directorship positions throughout his career. Mr. Walsh previously served as Vice President, Walsh & Kelly, Inc. (paving contractors).</p>

OFFICERS

Name

Birth Date

Address

Positions Held with Trust

Date Service Began

**Principal Occupation(s) for Past Five Years
and Previous Position(s)**

Lori A. Hensler

Birth Date: January 6, 1967

TREASURER

Officer since: April 2013

Principal Occupations: Principal Financial Officer and Treasurer of the Federated Hermes Fund Family; Senior Vice President, Federated Administrative Services; Financial and Operations Principal for Federated Securities Corp.; and Assistant Treasurer, Federated Investors Trust Company. Ms. Hensler has received the Certified Public Accountant designation.

Previous Positions: Controller of Federated Hermes, Inc.; Senior Vice President and Assistant Treasurer, Federated Investors Management Company; Treasurer, Federated Investors Trust Company; Assistant Treasurer, Federated Administrative Services, Federated Administrative Services, Inc., Federated Securities Corp., Edgewood Services, Inc., Federated Advisory Services Company, Federated Equity Management Company of Pennsylvania, Federated Global Investment Management Corp., Federated Investment Counseling, Federated Investment Management Company, Passport Research, Ltd., and Federated MDTA, LLC; Financial and Operations Principal for Federated Securities Corp., Edgewood Services, Inc. and Southpointe Distribution Services, Inc.

Peter J. Germain

Birth Date:

September 3, 1959

CHIEF LEGAL OFFICER,
SECRETARY AND EXECUTIVE
VICE PRESIDENT

Officer since: January 2005

Principal Occupations: Mr. Germain is Chief Legal Officer, Secretary and Executive Vice President of the Federated Hermes Fund Family. He is General Counsel, Chief Legal Officer, Secretary and Executive Vice President, Federated Hermes, Inc.; Trustee and Senior Vice President, Federated Investors Management Company; Trustee and President, Federated Administrative Services; Director and President, Federated Administrative Services, Inc.; Director and Vice President, Federated Securities Corp.; Director and Secretary, Federated Private Asset Management, Inc.; Secretary, Federated Shareholder Services Company; and Secretary, Retirement Plan Service Company of America. Mr. Germain joined Federated Hermes, Inc. in 1984 and is a member of the Pennsylvania Bar Association.

Previous Positions: Deputy General Counsel, Special Counsel, Managing Director of Mutual Fund Services, Federated Hermes, Inc.; Senior Vice President, Federated Services Company; and Senior Corporate Counsel, Federated Hermes, Inc.

Stephen Van Meter

Birth Date: June 5, 1975

CHIEF COMPLIANCE
OFFICER AND SENIOR
VICE PRESIDENT

Officer since: July 2015

Principal Occupations: Senior Vice President and Chief Compliance Officer of the Federated Hermes Fund Family; Vice President and Chief Compliance Officer of Federated Hermes, Inc. and Chief Compliance Officer of certain of its subsidiaries. Mr. Van Meter joined Federated Hermes, Inc. in October 2011. He holds FINRA licenses under Series 3, 7, 24 and 66.

Previous Positions: Mr. Van Meter previously held the position of Compliance Operating Officer, Federated Hermes, Inc. Prior to joining Federated Hermes, Inc., Mr. Van Meter served at the United States Securities and Exchange Commission in the positions of Senior Counsel, Office of Chief Counsel, Division of Investment Management and Senior Counsel, Division of Enforcement.

Name Birth Date Address Positions Held with Trust Date Service Began	Principal Occupation(s) for Past Five Years and Previous Position(s)
Stephen F. Auth Birth Date: September 13, 1956 101 Park Avenue 41 st Floor New York, NY 10178 CHIEF INVESTMENT OFFICER Officer since: November 2002	Principal Occupations: Stephen F. Auth is Chief Investment Officer of various Funds in the Federated Hermes Fund Family; Executive Vice President, Federated Investment Counseling, Federated Global Investment Management Corp. and Federated Equity Management Company of Pennsylvania. Previous Positions: Executive Vice President, Federated Investment Management Company and Passport Research, Ltd. (investment advisory subsidiary of Federated); Senior Vice President, Global Portfolio Management Services Division; Senior Vice President, Federated Investment Management Company and Passport Research, Ltd.; Senior Managing Director and Portfolio Manager, Prudential Investments.

Evaluation and Approval of Advisory Contract – May 2022

FEDERATED HERMES KAUFMANN FUND (THE “FUND”)

At its meetings in May 2022 (the “May Meetings”), the Fund’s Board of Trustees (the “Board”), including those Trustees who are not “interested persons” of the Fund, as defined in the Investment Company Act of 1940 (the “Independent Trustees”), reviewed and unanimously approved the continuation of the investment advisory contract between the Fund and Federated Equity Management Company of Pennsylvania (the “Adviser”) and the investment subadvisory contract between the Adviser and Federated Global Investment Management Corp. (the “Sub-Adviser” and together with the Adviser, the “Advisers”) with respect to the Fund (together, the “Contracts”) for an additional one-year term. The Board’s determination to approve the continuation of the Contracts reflects the exercise of its business judgment after considering all of the information and factors believed to be relevant and appropriate on whether to approve the continuation of the existing arrangements. The information, factors and conclusions that formed the basis for the Board’s approval are summarized below.

Information Received and Review Process

At the request of the Independent Trustees, the Fund’s Chief Compliance Officer (the “CCO”) furnished to the Board in advance of its May Meetings an independent written evaluation presenting on the topics discussed below. The Board considered the CCO’s independent written evaluation (the “CCO Fee Evaluation Report”), along with other information, in evaluating the reasonableness of the Fund’s management fee and in determining to approve the continuation of the Contracts. The CCO, in preparing the CCO Fee Evaluation Report, has the authority to retain consultants, experts or staff as reasonably necessary to assist in the performance of his duties, reports directly to the Board, and can be terminated only with the approval of a majority of the Independent Trustees. At the request of the Independent Trustees, the CCO Fee Evaluation Report followed the same general approach and covered the same topics as that of the report that had previously been delivered by the CCO in his capacity as “Senior Officer” prior to the elimination of the Senior Officer position in December 2017.

In addition to the extensive materials that comprise and accompany the CCO Fee Evaluation Report, the Board considered information specifically prepared in connection with the approval of the continuation of the Contracts that was presented at the May Meetings. In this regard, in the months preceding the May Meetings, the Board requested and reviewed written responses and supporting materials prepared by the Advisers and their affiliates (collectively, “Federated Hermes”) in response to requests posed to Federated Hermes by independent legal counsel on behalf of the Independent Trustees encompassing a wide variety of topics, including those summarized below. The Board also

considered such additional matters as the Independent Trustees deemed reasonably necessary to evaluate the Contracts, which included detailed information about the Fund and Federated Hermes furnished to the Board at its meetings throughout the year and in between regularly scheduled meetings on particular matters as the need arose.

The Board's consideration of the Contracts included review of materials and information covering the following matters, among others: the nature, quality and extent of the advisory and other services provided to the Fund by the Advisers and their affiliates; Federated Hermes' business and operations; the Advisers' investment philosophy, personnel and processes; the Fund's investment objectives and strategies; the Fund's short-term and long-term performance (in absolute terms, both on a gross basis and net of expenses, and relative to the Fund's particular investment program and a group of its peer funds and/or its benchmark, as appropriate); the Fund's fees and expenses, including the advisory fee and the overall expense structure of the Fund (both in absolute terms and relative to a group of its peer funds), with due regard for contractual or voluntary expense limitations (if any); the financial condition of Federated Hermes; the Adviser's profitability with respect to the Fund; distribution and sales activity for the Fund; and the use and allocation of brokerage commissions derived from trading the Fund's portfolio securities (if any).

The Board also considered judicial decisions concerning allegedly excessive investment advisory fees charged to other registered funds in determining to approve the Contracts. Using these judicial decisions as a guide, the Board observed that the following factors may be relevant to an adviser's fiduciary duty with respect to its receipt of compensation from a fund: (1) the nature and quality of the services provided by the adviser to the fund and its shareholders, including the performance of the fund, its benchmark and comparable funds; (2) the adviser's cost of providing the services and the profitability to the adviser of providing advisory services to the fund; (3) the extent to which the adviser may realize "economies of scale" as the fund grows larger and, if such economies of scale exist, whether they have been appropriately shared with the fund and its shareholders or the family of funds; (4) any "fall-out" benefits that accrue to the adviser because of its relationship with the fund, including research services received from brokers that execute fund trades and any fees paid to affiliates of the adviser for services rendered to the fund; (5) comparative fee and expense structures, including a comparison of management fees paid to the adviser with those paid by similar funds both internally and externally as well as management fees charged to institutional and other advisory clients of the adviser for what might be viewed as like services; and (6) the extent of care, conscientiousness and independence with which the fund's board members perform their duties and their expertise, including whether they are fully informed about all facts the board deems relevant to its consideration of the adviser's services and fees. The Board noted

that the Securities and Exchange Commission (“SEC”) disclosure requirements regarding the basis for a fund board’s approval of the fund’s investment advisory contract generally align with the factors listed above. The Board was guided by these factors in its review of the Contracts to the extent it considered them to be appropriate and relevant, as discussed further below. The Board considered and weighed these factors in light of its substantial accumulated experience in governing the Fund and working with Federated Hermes on matters relating to the oversight of the other funds advised by Federated Hermes (each, a “Federated Hermes Fund” and, collectively, the “Federated Hermes Funds”).

In addition to considering the above-referenced factors, the Board was mindful of the preferences and expectations of Fund shareholders and the potential disruptions of the Fund’s operations and various risks, uncertainties and other effects that could occur as a result of a decision to terminate or not renew the Contracts. In particular, the Board recognized that many shareholders likely have invested in the Fund on the strength of Federated Hermes’ industry standing and reputation and with the expectation that Federated Hermes will have a continuing role in providing advisory services to the Fund. Thus, the Board observed that in the marketplace there are a range of investment options available to the Fund’s shareholders and such shareholders, having had the opportunity to consider other investment options, have effectively selected Federated Hermes by virtue of investing in the Fund.

In determining to approve the continuation of the Contracts, the members of the Board reviewed and evaluated information and factors they believed to be relevant and appropriate through the exercise of their reasonable business judgment. While individual members of the Board may have weighed certain factors differently, the Board’s determination to approve the continuation of the Contracts was based on a comprehensive consideration of all information provided to the Board throughout the year and specifically with respect to the continuation of the Contracts. The Board recognized that its evaluation process is evolutionary and that the factors considered and emphasis placed on relevant factors may change in recognition of changing circumstances in the registered fund marketplace. The Independent Trustees were assisted throughout the evaluation process by independent legal counsel. In connection with their deliberations at the May Meetings, the Independent Trustees met separately in executive session with their independent legal counsel and without management present to review the relevant materials and consider their responsibilities under applicable laws. In addition, senior management representatives of Federated Hermes also met with the Independent Trustees and their independent legal counsel to discuss the materials and presentations furnished to the Board at the May Meetings. The Board considered the approval of the Contracts for the Fund as part of its consideration of agreements for funds across the family of Federated Hermes Funds, but its approvals were made on a fund-by-fund basis.

Nature, Extent and Quality of Services

The Board considered the nature, extent and quality of the services provided to the Fund by the Advisers and the resources of Federated Hermes dedicated to the Fund. In this regard, the Board evaluated, among other things, the terms of the Contracts and the range of services provided to the Fund by Federated Hermes. The Board considered the Advisers' personnel, investment philosophy and process, investment research capabilities and resources, trade operations capabilities, experience and performance track record. The Board reviewed the qualifications, backgrounds and responsibilities of the portfolio management team primarily responsible for the day-to-day management of the Fund and Federated Hermes' ability and experience in attracting and retaining qualified personnel to service the Fund. The Board also considered the Advisers' ability to deliver competitive investment performance for the Fund when compared to the Fund's Performance Peer Group (as defined below), which was deemed by the Board to be a useful indicator of how the Advisers are executing the Fund's investment program.

In addition, the Board considered the financial resources and overall reputation of Federated Hermes and its willingness to consider and make investments in personnel, infrastructure, technology, cybersecurity, business continuity planning and operational enhancements that are designed to benefit the Federated Hermes Funds. The Board noted the significant acquisition of Hermes Fund Managers Limited by Federated Hermes, which has deepened the organization's investment management expertise and capabilities and expanded the investment process for all of the Federated Hermes Funds to have access to analytical resources related to environmental, social and governance ("ESG") factors and issuer engagement on ESG matters. The Board considered Federated Hermes' oversight of the securities lending program for the Federated Hermes Funds that engage in securities lending and noted the income earned by the Federated Hermes Funds that participate in such program. In addition, the Board considered the quality of Federated Hermes' communications with the Board and responsiveness to Board inquiries and requests made from time to time with respect to the Fund and other Federated Hermes Funds. In this regard, the Board took into account Federated Hermes' communications with the Board in light of the pandemic. The Board also considered that Federated Hermes is responsible for providing the Federated Hermes Funds' officers.

The Board received and evaluated information regarding Federated Hermes' regulatory and compliance environment. The Board considered Federated Hermes' compliance program and compliance history and reports from the CCO about Federated Hermes' compliance with applicable laws and regulations, including responses to regulatory developments and any compliance or other issues raised by regulatory agencies. The Board also noted Federated Hermes' support of the Federated Hermes Funds' compliance control structure and the compliance-related resources devoted by Federated

Hermes in support of the Fund's obligations pursuant to Rule 38a-1 under the Investment Company Act of 1940, including Federated Hermes' commitment to respond to rulemaking and other regulatory initiatives of the SEC. The Board considered Federated Hermes' approach and risk management with respect to the Federated Hermes Funds and its day-to-day oversight of the Federated Hermes Funds' compliance with their investment objectives and policies as well as with applicable laws and regulations, noting that regulatory and other developments had over time led to an increase in the scope of Federated Hermes' oversight in this regard, including in connection with the designation of the Federated Hermes Funds' investment advisers as the administrators of the Federated Hermes Funds' liquidity risk management program.

The Board also considered the implementation of Federated Hermes' business continuity plans and recognized steps taken by Federated Hermes to continue to provide the same nature, extent and quality of services to the Federated Hermes Funds during the pandemic. In addition, the Board noted Federated Hermes' commitment to maintaining high quality systems and expending substantial resources to prepare for and respond to ongoing changes due to the market, regulatory and control environments in which the Fund and its service providers operate, including changes associated with the pandemic.

The Board considered Federated Hermes' efforts to provide shareholders in the Federated Hermes Funds with a comprehensive array of funds with different investment objectives, policies and strategies. The Board considered the expenses that Federated Hermes had incurred, as well as the entrepreneurial and other risks assumed by Federated Hermes, in sponsoring and providing ongoing services to new funds to expand these opportunities for shareholders. The Board noted the benefits to shareholders of being part of the family of Federated Hermes Funds, which include the general right to exchange investments between the same class of shares without the incurrence of additional sales charges.

Based on these considerations, the Board concluded that it was satisfied with the nature, extent and quality of the services provided by the Advisers to the Fund.

Fund Investment Performance

The Board considered the investment performance of the Fund. In evaluating the Fund's investment performance, the Board considered performance results in light of the Fund's investment objective, strategies and risks. The Board considered detailed investment reports on, and the Advisers' analysis of, the Fund's performance over different time periods that were provided to the Board throughout the year and in connection with the May Meetings. These reports include, among other items, information on the Fund's

gross and net returns, the Fund’s investment performance compared to one or more relevant categories or groups of peer funds and the Fund’s benchmark index, performance attribution information and commentary on the effect of market conditions.

The Board also reviewed comparative information regarding the performance of other registered funds in the category of peer funds selected by Morningstar, Inc. (the “Morningstar”), an independent fund ranking organization (the “Performance Peer Group”). The Board noted the CCO’s view that comparisons to fund peer groups may be helpful, though not conclusive, in evaluating the performance of the Advisers in managing the Fund. The Board considered, in evaluating such comparisons, that in some cases there may be differences in the funds’ objectives or investment management techniques, or the costs to implement the funds, even within the same Performance Peer Group. In this connection, the Board considered that the longevity and experience of the Fund’s portfolio management team and its extensive bottom-up approach to investing may limit the utility of comparisons to other equity mutual funds.

The Fund’s performance fell below the median of the Performance Peer Group for the one-year, three-year and five-year periods ended December 31, 2021. The Board discussed the Fund’s performance with the Advisers and recognized the efforts being taken by the Advisers in the context of other factors considered relevant by the Board.

Based on these considerations, the Board concluded that it had continued confidence in the Advisers’ overall capabilities to manage the Fund.

Fund Expenses

The Board considered the advisory fee, sub-advisory fee, and overall expense structure of the Fund and the comparative fee and expense information that had been provided in connection with the May Meetings. In this regard, the Board was presented with, and considered, information regarding the contractual advisory fee rates, net advisory fee rates, total expense ratios and each element of the Fund’s total expense ratio (i.e., gross and net advisory fees, administrative fees, custody fees, portfolio accounting fees and transfer agency fees) relative to an appropriate group of peer funds compiled by Federated Hermes from the category of peer funds selected by Morningstar (the “Expense Peer Group”). The Board received a description of the methodology used to select the Expense Peer Group from the overall Morningstar category. The Board also reviewed comparative information regarding the fees and expenses of the broader group of funds in the overall Morningstar category. In addition, the Board received and considered comparative fee information for a group of unregistered hedge funds that employ equity strategies similar to the Fund from an independent third-party provider of alternative assets data.

While mindful that courts have cautioned against giving too much weight to comparative information concerning fees charged by other advisers for managing funds with comparable investment programs, the Board noted that it found the use of such comparisons to be relevant to its evaluation. The Board focused on comparisons with other similar registered funds more heavily than non-registered fund products or services because such comparisons are believed to be more relevant. The Board considered that other registered funds are the products most like the Fund, in that they are readily available to Fund shareholders as alternative investment vehicles, and they are the type of investment vehicle, in fact, chosen and maintained by the Fund's shareholders. The Board noted that the range of such other registered funds' fees and expenses, therefore, appears to be a relevant indicator of what investors have found to be reasonable in the marketplace in which the Fund competes.

The Board reviewed the contractual advisory fee rate, net advisory fee rate and other expenses of the Fund and noted the position of the Fund's fee rates relative to its Expense Peer Group. In this regard, the Board noted that the contractual advisory fee rate was above the median of the Expense Peer Group, but the Board noted the applicable waivers and reimbursements, and that the overall expense structure of the Fund remained competitive in the context of other factors considered by the Board. The Board considered the CCO's view that, in 2021, while the Fund's expenses were above median relative to its Expense Peer Group, those expenses remained reasonable in light of its extensive bottom-up investment process, the relative expense of that process, the resulting estimated profitability of the Fund over time, and the performance generated over time compared to peer funds. The Board considered the fact that the Adviser committed to permanently replace the Fund's current contractual investment advisory fee rate of 1.30% with an investment advisory fee schedule that imposes an advisory fee rate of 1.275% on assets up to \$8 billion and incorporates breakpoints that reduce fee rates upon the Fund reaching \$8 billion, \$9 billion, \$10 billion and \$12 billion in size, such changes to be effective July 1, 2022. The Board noted that these changes would result in a reduction in the Fund's gross advisory fee.

The Board also received and considered information about the fees charged by Federated Hermes for providing advisory services to other types of clients with investment strategies similar to those of the Federated Hermes Funds, including non-registered fund clients (such as institutional separate accounts) and third-party unaffiliated registered funds for which any of the Advisers or their affiliates serve as sub-adviser. The Board noted the CCO's conclusion that non-registered fund clients are inherently different products due to the following differences, among others: (i) different types of targeted investors; (ii) different applicable laws and regulations; (iii) different legal structures; (iv) different average account sizes and portfolio management techniques made necessary by different cash flows and different associated costs; (v) the time spent by portfolio managers and their teams (among other personnel across

various departments, including legal, compliance and risk management) in reviewing securities pricing and fund liquidity; (vi) different administrative responsibilities; (vii) different degrees of risk associated with management; and (viii) a variety of different costs. The Board also considered information regarding the differences in the nature of the services required for Federated Hermes to manage its proprietary registered fund business versus managing a discrete pool of assets as a sub-adviser to another institution's registered fund, noting the CCO's view that Federated Hermes generally performs significant additional services and assumes substantially greater risks in managing the Fund and other Federated Hermes Funds than in its role as sub-adviser to an unaffiliated third-party registered fund. The Board noted that the CCO did not consider the fees for providing advisory services to other types of clients to be determinative in judging the appropriateness of the Federated Hermes Funds' advisory fees.

In the case of the Fund, the Board noted that Federated Hermes does not manage any other types of clients that are comparable to the Fund.

Based on these considerations, the Board concluded that the fees and total operating expenses of the Fund, in conjunction with other matters considered, are reasonable in light of the services provided.

Profitability

The Board received and considered profitability information furnished by Federated Hermes, as requested by the CCO. Such profitability information included revenues reported on a fund-by-fund basis and estimates of the allocation of expenses made on a fund-by-fund basis, using allocation methodologies specified by the CCO and described to the Board. The Board considered the CCO's view that, while these cost allocation reports apply consistent allocation processes, the inherent difficulties in allocating costs on a fund-by-fund basis continues to cause the CCO to question the precision of the process and to conclude that such reports may be unreliable because a single change in an allocation estimate may dramatically alter the resulting estimate of cost and/or profitability of a Federated Hermes Fund and may produce unintended consequences. In addition, the Board considered the CCO's view that the allocation methodologies used by Federated Hermes in estimating profitability for purposes of reporting to the Board in connection with the continuation of the Contracts are consistent with the methodologies previously reviewed by an independent consultant. The Board noted that the independent consultant had previously conducted a review of the allocation methodologies and reported that, although there is no single best method to allocate expenses, the methodologies used by Federated Hermes are reasonable.

The Board also reviewed information compiled by Federated Hermes comparing its profitability information to other publicly held fund management companies, including information regarding profitability trends over time. The Board considered the CCO's conclusion that, based on such profitability

information, Federated Hermes' profit margins did not appear to be excessive. The Board also considered the CCO's view that Federated Hermes appeared financially sound, with the resources necessary to fulfill its obligations under its contracts with the Federated Hermes Funds.

Economies of Scale

The Board received and considered information about the notion of possible realization of "economies of scale" as a fund grows larger, the difficulties of calculating economies of scale at an individual fund level, and the extent to which potential scale benefits are shared with shareholders. In this regard, the Board considered that Federated Hermes has made significant and long-term investments in areas that support all of the Federated Hermes Funds, such as: personnel, processes and tools for portfolio management, including the use of market data on which portfolio managers make investment decisions; trading operations; ESG integration and issuer engagement on ESG matters; shareholder services; compliance; business continuity; cybersecurity; internal audit and risk management functions; and technology that supports the provision of investment management services. The Board noted that Federated Hermes' investments in these areas are extensive and are designed to provide enhanced services to the Federated Hermes Funds and their shareholders. The Board considered that the benefits of these investments are likely to be shared with the family of Federated Hermes Funds as a whole. In addition, the Board considered that fee waivers and expense reimbursements are another means for potential economies of scale to be shared with shareholders and can provide protection from an increase in expenses if a Federated Hermes Fund's assets decline. The Board considered that, in order for the Federated Hermes Funds to remain competitive in the marketplace, Federated Hermes has frequently waived fees and/or reimbursed expenses for the Federated Hermes Funds and has disclosed to shareholders and/or reported to the Board its intention to do so (or continue to do so) in the future. The Board also considered Federated Hermes' reductions in contractual management fees for certain Federated Hermes Funds during the prior year, including in response to the CCO's recommendations in the prior year's CCO Fee Evaluation Report, which have resulted in benefits being realized by shareholders.

The Board also considered reports on adviser-paid fees (commonly referred to as "revenue sharing") that were provided to the Board throughout the year and in connection with the May Meetings. The Board considered that Federated Hermes and the CCO believe that this information should be viewed to determine if there was an incentive to either not apply breakpoints, or to apply breakpoints at higher levels, and should not be viewed to evaluate the reasonableness of advisory fees. The Board also noted the absence of any applicable regulatory or industry guidelines on this subject, which is compounded by the lack of any uniform methodology or pattern with respect to structuring fund advisory fees with breakpoints that serve to reduce the fees as a fund attains a certain size.

The Board noted the provisions agreed upon in the settlement of the Kaufmann Fund fee litigation under which, starting July 1, 2012 and for a period of ten years thereafter, a cap on the net investment advisory fee is imposed and under which additional breakpoints are required upon the Fund reaching \$8 billion, \$9 billion, \$10 billion and \$12 billion in size. The Board further noted that, in light of the expiration of the settlement provisions on June 30, 2022, Federated Hermes recommended at the May Meetings that the breakpoints described above be incorporated into the Fund's contractual investment advisory fee schedule, to be effective July 1, 2022, which would result in a reduction in the Fund's gross advisory fee.

Other Benefits

The Board considered information regarding the compensation and other ancillary (or "fall-out") benefits that Federated Hermes derived from its relationships with the Federated Hermes Funds. The Board noted that, in addition to receiving advisory fees under the Federated Hermes Funds' investment advisory contracts, Federated Hermes' affiliates also receive fees for providing other services to the Federated Hermes Funds under separate contracts (e.g., for serving as the Federated Hermes Funds' administrator and distributor). In this regard, the Board considered that certain of Federated Hermes' affiliates provide distribution and shareholder services to the Federated Hermes Funds, for which they may be compensated through distribution and servicing fees paid pursuant to Rule 12b-1 plans or otherwise. The Board also received and considered information detailing any indirect benefit that Federated Hermes may derive from its receipt of research services from brokers who execute portfolio trades for the Federated Hermes Funds.

Conclusions

The Board considered: (i) the CCO's conclusion that his observations and the information accompanying the CCO Fee Evaluation Report show that the management fee for the Fund is reasonable; and (ii) the CCO's recommendation that the Board approve the management fee. The Board noted that, under these circumstances, no changes were recommended to, and no objection was raised to the continuation of, the Contracts by the CCO. The CCO also recognized that the Board's evaluation of the Federated Hermes Funds' advisory and sub-advisory arrangements is a continuing and ongoing process that is informed by the information that the Board requests and receives from management throughout the course of the year and, in this regard, the CCO noted certain items for future reporting to the Board or further consideration by management as the Board continues its ongoing oversight of the Federated Hermes Funds.

On the basis of the information and factors summarized above, among other information and factors deemed relevant by the Board, and the evaluation thereof, the Board, including the Independent Trustees, unanimously voted to approve the continuation of the Contracts. The Board based its determination

to approve the Contracts on the totality of the circumstances and relevant factors and with a view of past and future long-term considerations. Not all of the factors and considerations identified above were necessarily deemed to be relevant to the Fund, nor did the Board consider any one of them to be determinative. With respect to the factors that were deemed to be relevant, the Board's determination to approve the continuation of the Contracts reflects its view that Federated Hermes' performance and actions provided a satisfactory basis to support the determination to approve the continuation of the existing arrangements.

Liquidity Risk Management Program – Annual Evaluation of Adequacy and Effectiveness

In accordance with Rule 22e-4 under the Investment Company Act of 1940, as amended (the “Liquidity Rule”), Federated Hermes Equity Funds (the “Trust”) has adopted and implemented a liquidity risk management program (the “Program”) for Federated Hermes Kaufmann Fund (the “Fund”) and, collectively with the other non-money market open-end funds advised by Federated Hermes, the “Federated Hermes Funds”). The Program seeks to assess and manage the Fund’s liquidity risk. “Liquidity risk” is defined under the Liquidity Rule as the risk that the Fund is unable to meet redemption requests without significantly diluting remaining investors’ interests in the Fund. The Board of Trustees of the Trust (the “Board”) has approved the designation of each Federated Hermes Fund’s investment adviser as the administrator for the Program (the “Administrator”) with respect to that Fund. The Administrator, in turn, has delegated day-to-day responsibility for the administration of the Program to multiple Liquidity Risk Management Committees, which are comprised of representatives from certain divisions within Federated Hermes.

The Program is comprised of various components designed to support the assessment and/or management of liquidity risk, including: (1) the periodic assessment (no less frequently than annually) of certain factors that influence the Fund’s liquidity risk; (2) the periodic classification (no less frequently than monthly) of the Fund’s investments into one of four liquidity categories that reflect an estimate of their liquidity under current market conditions; (3) a 15% limit on the acquisition of “illiquid investments” (as defined under the Liquidity Rule); (4) to the extent a Fund does not invest primarily in “highly liquid investments” (as defined under the Liquidity Rule), the determination of a minimum percentage of the Fund’s assets that generally will be invested in highly liquid investments (an “HLIM”); (5) if a Fund has established an HLIM, the periodic review (no less frequently than annually) of the HLIM and the adoption of policies and procedures for responding to a shortfall of the Fund’s highly liquid investments below its HLIM; and (6) periodic reporting to the Board.

At its meetings in May 2022, the Board received and reviewed a written report (the “Report”) from the Federated Hermes Funds’ Chief Compliance Officer and Chief Risk Officer, on behalf of the Administrator, concerning the operation of the Program for the period from April 1, 2021 through March 31, 2022 (the “Period”). The Report addressed the operation of the Program and assessed its adequacy and effectiveness, including, where applicable, the operation of any HLIM established for a Federated Hermes Fund and each Federated Hermes Fund’s access to other available funding sources such as the Federated Hermes Funds’ interfund lending facility, redemptions in-kind, reverse repurchase agreement transactions, redemptions

delayed beyond the normal T+1 settlement, but within seven days of the redemption request, and committed lines of credit. There were no material changes to the Program during the Period. The Report summarized the operation of the Program and the information and factors considered by the Administrator in assessing whether the Program has been adequately and effectively implemented with respect to the Federated Hermes Funds. Such information and factors included, among other things:

- confirmation that it was not necessary for the Fund to utilize, and the Fund did not utilize, alternative funding sources during the Period;
- the periodic classifications of the Fund's investments into one of four liquidity categories and the methodologies and inputs used to classify the investments, including the Fund's reasonably anticipated trade size;
- the analysis received from a third-party liquidity assessment vendor that is taken into account in the process of determining the liquidity classifications of the Fund's investments and the results of an evaluation of the services performed by the vendor in support of this process;
- the fact that the Fund invested primarily in highly liquid investments during the Period and, therefore, was not required to establish, and has not established, an HLIM and the procedures for monitoring the status of the Fund as investing primarily in highly liquid investments;
- the fact that the Fund invested no more than 15% of its assets in illiquid investments during the Period and the procedures for monitoring this limit;
- the fact that there were no liquidity events during the Period, that materially affected the Fund's liquidity risk;
- the impact on liquidity and management of liquidity risk caused by extended non-U.S. market closures and confirmation that there were no issues for any of the affected Federated Hermes Funds in meeting shareholder redemptions at any time during these temporary non-U.S. market closures;
- circumstances during the Period under which the Administrator convened meetings of the Liquidity Risk Management Committees more frequently than normal to conduct enhanced liquidity risk monitoring, including prior to the Russian invasion of Ukraine.

Based on this review, the Administrator concluded that the Program is operating effectively to assess and manage the Fund's liquidity risk, and that the Program has been and continues to be adequately and effectively implemented to monitor and, as applicable, respond to the Fund's liquidity developments.

Voting Proxies on Fund Portfolio Securities

A description of the policies and procedures that the Fund uses to determine how to vote proxies, if any, relating to securities held in the Fund's portfolio is available, without charge and upon request, by calling 1-800-341-7400, Option #4. A report on "Form N-PX" of how the Fund voted any such proxies during the most recent 12-month period ended June 30 is available via the Proxy Voting Record (Form N-PX) link associated with the Fund and share class name at [FederatedInvestors.com/FundInformation](https://www.federatedinvestors.com/fundinformation). Form N-PX filings are also available at the SEC's website at [sec.gov](https://www.sec.gov).

Quarterly Portfolio Schedule

Each fiscal quarter, the Fund will file with the SEC a complete schedule of its monthly portfolio holdings on "Form N-PORT." The Fund's holdings as of the end of the third month of every fiscal quarter, as reported on Form N-PORT, will be publicly available on the SEC's website at [sec.gov](https://www.sec.gov) within 60 days of the end of the fiscal quarter upon filing. You may also access this information via the link to the Fund and share class name at [FederatedInvestors.com](https://www.federatedinvestors.com).

Notes

Notes

Notes

Mutual funds are not bank deposits or obligations, are not guaranteed by any bank and are not insured or guaranteed by the U.S. government, the Federal Deposit Insurance Corporation, the Federal Reserve Board or any other government agency. Investment in mutual funds involves investment risk, including the possible loss of principal.

This Report is authorized for distribution to prospective investors only when preceded or accompanied by the Fund's Prospectus, which contains facts concerning its objective and policies, management fees, expenses and other information.

Sign up for Electronic Delivery!

A faster way to receive documents.

If you purchased shares through a financial intermediary (bank or broker-dealer), please contact your representative to set up e-delivery. Otherwise, contact the Fund at 1-800-341-7400, Option #4.

Federated Hermes

Federated Hermes Kaufmann Fund
Federated Hermes Funds
4000 Ericsson Drive
Warrendale, PA 15086-7561

Contact us at [FederatedInvestors.com](https://www.federatedinvestors.com)
or call 1-800-341-7400.

Federated Securities Corp., Distributor

CUSIP 314172677
CUSIP 314172669
CUSIP 314172651
CUSIP 314172644
CUSIP 31421N873

26396 (12/22)

© 2022 Federated Hermes, Inc.

